1
|
Perdiguero B, Hauser A, Gómez CE, Peterhoff D, Sideris E, Sorzano CÓS, Wilmschen S, Schaber M, Stengel L, Asbach B, Ding S, Von Laer D, Levy Y, Pantaleo G, Kimpel J, Esteban M, Wagner R. Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein. Front Immunol 2023; 14:1270908. [PMID: 38045703 PMCID: PMC10690772 DOI: 10.3389/fimmu.2023.1270908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 10/25/2023] [Indexed: 12/05/2023] Open
Abstract
Introduction The generation of an HIV-1 vaccine able to induce long-lasting protective immunity remains a main challenge. Here, we aimed to modify next-generation soluble, prefusion-stabilized, close-to-native, glycan-engineered clade C gp140 envelope (Env) trimers (sC23v4 KIKO and ConCv5 KIKO) for optimal display on the cell surface following homologous or heterologous vector delivery. Methods A combination of the following modifications scored best regarding the preservation of closed, native-like Env trimer conformation and antigenicity when using a panel of selected broadly neutralizing (bnAb) and non-neutralizing (nnAb) monoclonal antibodies for flow cytometry: i) replacing the natural cleavage site with a native flexible linker and introducing a single amino acid substitution to prevent CD4 binding (*), ii) fusing a heterologous VSV-G-derived transmembrane moiety to the gp140 C-terminus, and iii) deleting six residues proximal to the membrane. Results When delivering membrane-tethered sC23v4 KIKO* and ConCv5 KIKO* via DNA, VSV-GP, and NYVAC vectors, the two native-like Env trimers provide differential antigenicity profiles. Whereas such patterns were largely consistent among the different vectors for either Env trimer, the membrane-tethered ConCv5 KIKO* trimer adopted a more closed and native-like structure than sC23v4 KIKO*. In immunized mice, VSV-GP and NYVAC vectors expressing the membrane-tethered ConCv5 KIKO* administered in prime/boost combination were the most effective regimens for the priming of Env-specific CD4 T cells among all tested combinations. The subsequent booster administration of trimeric ConCv5 KIKO* Env protein preserved the T cell activation levels between groups. The evaluation of the HIV-1-specific humoral responses induced in the different immunization groups after protein boosts showed that the various prime/boost protocols elicited broad and potent antibody responses, preferentially of a Th1-associated IgG2a subclass, and that the obtained antibody levels remained high at the memory phase. Discussion In summary, we provide a feasible strategy to display multiple copies of native-like Env trimers on the cell surface, which translates into efficient priming of sustained CD4+ T cell responses after vector delivery as well as broad, potent, and sustained antibody responses following booster immunizations with the homologous, prefusion-stabilized, close-to-native ConCv5 KIKO* gp140 Env trimer.
Collapse
Affiliation(s)
- Beatriz Perdiguero
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Alexandra Hauser
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
| | - Carmen Elena Gómez
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - David Peterhoff
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
| | - Elefthéria Sideris
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Carlos Óscar S. Sorzano
- Biocomputing Unit and Computational Genomics, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Sarah Wilmschen
- Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
| | - Marion Schaber
- Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
| | - Laura Stengel
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
| | - Benedikt Asbach
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
| | - Song Ding
- EuroVacc Foundation, Lausanne, Switzerland
| | - Dorothee Von Laer
- Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
| | - Yves Levy
- Vaccine Research Institute (VRI), Université Paris-Est Créteil, Faculté de Médicine, Institut national de la santé et de la recherche médicale (INSERM) U955, Créteil, France
- Institut national de la santé et de la recherche médicale (INSERM) U955, Equipe 16, Créteil, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses, Créteil, France
| | - Giuseppe Pantaleo
- Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Janine Kimpel
- Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
| | - Mariano Esteban
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Ralf Wagner
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
- Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany
| |
Collapse
|
2
|
Blengio F, Hocini H, Richert L, Lefebvre C, Durand M, Hejblum B, Tisserand P, McLean C, Luhn K, Thiebaut R, Levy Y. Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo. Cell Rep 2023; 42:113101. [PMID: 37691146 DOI: 10.1016/j.celrep.2023.113101] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 07/24/2023] [Accepted: 08/21/2023] [Indexed: 09/12/2023] Open
Abstract
Ebola virus disease is a severe hemorrhagic fever with a high fatality rate. We investigate transcriptome profiles at 3 h, 1 day, and 7 days after vaccination with Ad26.ZEBOV and MVA-BN-Filo. 3 h after Ad26.ZEBOV injection, we observe an increase in genes related to antigen presentation, sensing, and T and B cell receptors. The highest response occurs 1 day after Ad26.ZEBOV injection, with an increase of the gene expression of interferon-induced antiviral molecules, monocyte activation, and sensing receptors. This response is regulated by the HESX1, ATF3, ANKRD22, and ETV7 transcription factors. A plasma cell signature is observed on day 7 post-Ad26.ZEBOV vaccination, with an increase of CD138, MZB1, CD38, CD79A, and immunoglobulin genes. We have identified early expressed genes correlated with the magnitude of the antibody response 21 days after the MVA-BN-Filo and 364 days after Ad26.ZEBOV vaccinations. Our results provide early gene signatures that correlate with vaccine-induced Ebola virus glycoprotein-specific antibodies.
Collapse
Affiliation(s)
- Fabiola Blengio
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France
| | - Hakim Hocini
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France
| | - Laura Richert
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France; University Bordeaux, Department of Public Health, INSERM Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, Bordeaux, France; CHU de Bordeaux, Pôle de Santé Publique, Service d'Information Médicale, Bordeaux, France
| | - Cécile Lefebvre
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France
| | - Mélany Durand
- University Bordeaux, Department of Public Health, INSERM Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, Bordeaux, France; CHU de Bordeaux, Pôle de Santé Publique, Service d'Information Médicale, Bordeaux, France
| | - Boris Hejblum
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France; University Bordeaux, Department of Public Health, INSERM Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, Bordeaux, France; CHU de Bordeaux, Pôle de Santé Publique, Service d'Information Médicale, Bordeaux, France
| | - Pascaline Tisserand
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France
| | - Chelsea McLean
- Janssen Vaccines & Prevention, B.V. Archimediesweg, Leiden, the Netherlands
| | - Kerstin Luhn
- Janssen Vaccines & Prevention, B.V. Archimediesweg, Leiden, the Netherlands
| | - Rodolphe Thiebaut
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France; University Bordeaux, Department of Public Health, INSERM Bordeaux Population Health Research Centre, Inria SISTM, UMR 1219, Bordeaux, France; CHU de Bordeaux, Pôle de Santé Publique, Service d'Information Médicale, Bordeaux, France.
| | - Yves Levy
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France.
| |
Collapse
|
3
|
Aerssens D, Miret-Casals L, Gomez D, Sousa-Neves D, Levy Y, De Vleesschouwer M, Manicardi A, Madder A. Photo-induced crosslinking uncovers an antiparallel strand orientation in heterodimeric (EIAALEK) 3/(KIAALKE) 3 and (EIAALEK) 3/(RIAALRE) 3 coiled-coil systems. Org Biomol Chem 2023. [PMID: 37394986 DOI: 10.1039/d2ob02181a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
Abstract
We describe for the first time the co-existence of the parallel and antiparallel conformation of the heterodimeric E3/K3 and E3/R3 coiled-coil systems in solution. The introduction of a furanylated amino acid in the (EIAALEK)3 sequence allowed, upon photo-induced covalent crosslinking, freezing of the respective coiled-coil complexes present in solution. The occurrence of both parallel and antiparallel conformations in solution was supported by computational simulations and further confirmed by fluorescence experiments based on pyrene-pyrene stacking.
Collapse
Affiliation(s)
- D Aerssens
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281-S4, Gent 9000, Belgium.
| | - L Miret-Casals
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281-S4, Gent 9000, Belgium.
| | - D Gomez
- Department of Biology and Chemistry, New York University, New York 10003, USA
| | - D Sousa-Neves
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281-S4, Gent 9000, Belgium.
| | - Y Levy
- Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel
| | - M De Vleesschouwer
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281-S4, Gent 9000, Belgium.
| | - A Manicardi
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281-S4, Gent 9000, Belgium.
- Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Viale delle Scienze, 17/A, I-43124 Parma, Italy
| | - A Madder
- Organic and Biomimetic Chemistry Research Group, Department of Organic and Macromolecular Chemistry, Ghent University, Krijgslaan 281-S4, Gent 9000, Belgium.
| |
Collapse
|
4
|
Melica G, Bartolucci P, Audureau E, Le Corvoisier P, Habibi A, Gellen J, Selmane D, Michel M, Lacabaratz C, Levy Y. Immunological Efficacy of Pneumococcal Vaccination Including the 13-Valent Pneumococcal Conjugate Vaccine in Adult Patients With Sickle Cell Disease: Results of the Randomized DREVAC Controlled Trial. Clin Infect Dis 2023; 76:1949-1958. [PMID: 36705266 DOI: 10.1093/cid/ciad037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 01/05/2023] [Accepted: 01/20/2023] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND Patients with sickle cell disease (SCD) are at high risk for invasive pneumococcal diseases. The immunological efficacy of 13-valent conjugate pneumococcal vaccine (PCV13) followed by a 23-valent polysaccharide vaccine (PPSV23) is poorly documented in adults with SCD. METHODS This was a randomized open-labeled phase 2 study of the immunogenicity of PCV13 at week 0, followed by PPSV23 at week 4, compared with PPSV23 alone at week 4 in adult patients with SCD. The proportion of responders (4-fold increase in serotype-specific immunoglobulin [Ig] G antibodies) to ≥10 shared serotypes was assessed at week 8. Secondary end points were (1) geometric mean titers, (2) responders to 0-1, 2-5, 6-9, or 10-12 serotypes, (3) pneumococcal opsonophagocytic activity, and (4) response durability at weeks 24 and 96. RESULTS In total, 128 patients were randomized in the PCV13/PPSV23 (n = 63) or PPSV23-alone groups (n = 65). At week 8, 24.56% and 8.20% of patients from the PCV13/PPSV23 and PPSV23 groups, respectively, reached the primary end point (P = .02). These numbers were 36.2% and 8.7% for opsonophagocytic activity responders (P = .002). A combined PCV13/PPSV23 strategy improved the breadth of responses to 0-1, 2-5, 6-9, or 10-12 serotypes with 15.8%, 35%, 24.6%, and 24.6% versus 52.5%, 31%, 8%, and 8% in the PPSV23 group. At week 96, geometric mean titers were significantly higher in the PCV13/PPSV23 than in the PPSV23-alone group for 5 serotypes (4, 14, 19A, 19F, 23F). CONCLUSIONS A PCV13/PPSV23 regimen improved the breadth and magnitude of antibody responses against a large range of pneumococcal serotypes in adults with SCD. The sustainability of the immune response requires recall strategies.Clinical Trial Registration: NCT02274415.
Collapse
Affiliation(s)
- Giovanna Melica
- Clinical Immunology and Infectious Diseases Unit, Henri Mondor Hospital, APHP, Creteil, France
- Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France
| | - Pablo Bartolucci
- Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France
| | - Etienne Audureau
- Public Health Department, Henri Mondor Hospital, APHP, Mondor Institut of Biomedical Research Inserm U955, University Paris Est Creteil, Creteil, France
| | - Philippe Le Corvoisier
- Clinical Investigation Center 1430, Inserm, Henri Mondor Hospital, APHP, Creteil, France
| | - Anoosha Habibi
- Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France
| | - Justine Gellen
- Sickle Cell Referral Center, Red Cell Genetic Diseases Unit, Henri Mondor Hospital, APHP, and University Paris Est Creteil, Mondor Institut of Biomedical Research, Laboratory of Excellence, Creteil, France
| | - Dalia Selmane
- Public Health Department, Henri Mondor Hospital, APHP, Mondor Institut of Biomedical Research Inserm U955, University Paris Est Creteil, Creteil, France
| | - Marc Michel
- Internal Medicine Unit, Henri Mondor Hospital, APHP, Creteil, France
| | - Christine Lacabaratz
- Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France
| | - Yves Levy
- Clinical Immunology and Infectious Diseases Unit, Henri Mondor Hospital, APHP, Creteil, France
- Vaccine Research Institute, Inserm U955 Equipe 16, University Paris Est, Creteil, France
| |
Collapse
|
5
|
Zukerstein M, Levy Y. Enhancement of the spectral broadening efficiency for circular polarization states in the high absorption regime for Gaussian and doughnut-shaped beams in fused silica. Opt Express 2023; 31:16295-16302. [PMID: 37157711 DOI: 10.1364/oe.485881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
We experimentally investigate the spectral broadening in fused silica in the multiphoton absorption regime. Under standard conditions of laser irradiation, linear polarization of laser pulses is more advantageous for supercontinuum generation. However, with high non-linear absorption, we observe more efficient spectral broadening for circular polarizations for both Gaussian and doughnut-shaped beams. The multiphoton absorption in fused silica is studied by measuring the total transmission of laser pulses and by the intensity dependence of the self-trapped exciton luminescence observation. The strong polarization dependence of multiphoton transitions fundamentally affects the broadening of the spectrum in solids.
Collapse
|
6
|
Gressens SB, Wiedemann A, Déchenaud M, Dupuis J, Gallien S, Melica G, Haioun C, Lemonnier F, Levy Y. Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies. Vaccine 2023; 41:1550-1553. [PMID: 36737320 PMCID: PMC9884622 DOI: 10.1016/j.vaccine.2023.01.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 11/28/2022] [Accepted: 01/25/2023] [Indexed: 01/31/2023]
Abstract
Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vaccine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 therapies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4+Th1+T cell responses while the effect CD8 + T cell responses was marginal.
Collapse
Affiliation(s)
- Simon B Gressens
- Infectious Diseases and Immunology Department, Hôpital Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris - Université Paris Est Créteil, France.
| | - Aurélie Wiedemann
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France; Univ Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France
| | - Marie Déchenaud
- Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France
| | - Jehan Dupuis
- IAP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Service Unité Hémopathies Lymphoides, F-94010 Créteil, France
| | - Sébastien Gallien
- Infectious Diseases and Immunology Department, Hôpital Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris - Université Paris Est Créteil, France; Univ Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France
| | - Giovanna Melica
- Infectious Diseases and Immunology Department, Hôpital Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris - Université Paris Est Créteil, France; Univ Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France.
| | - Corinne Haioun
- IAP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Service Unité Hémopathies Lymphoides, F-94010 Créteil, France; Univ Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France
| | - François Lemonnier
- IAP-HP, Groupe hospitalo-universitaire Chenevier Mondor, Service Unité Hémopathies Lymphoides, F-94010 Créteil, France; Univ Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France
| | - Yves Levy
- Infectious Diseases and Immunology Department, Hôpital Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris - Université Paris Est Créteil, France; Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France.
| |
Collapse
|
7
|
Battey E, Ross JA, Hoang A, Wilson DGS, Han Y, Levy Y, Pollock RD, Kalakoutis M, Pugh JN, Close GL, Ellison-Hughes GM, Lazarus NR, Iskratsch T, Harridge SDR, Ochala J, Stroud MJ. Myonuclear alterations associated with exercise are independent of age in humans. J Physiol 2023. [PMID: 36597809 DOI: 10.1113/jp284128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Accepted: 12/19/2022] [Indexed: 01/05/2023] Open
Abstract
Age-related decline in skeletal muscle structure and function can be mitigated by regular exercise. However, the precise mechanisms that govern this are not fully understood. The nucleus plays an active role in translating forces into biochemical signals (mechanotransduction), with the nuclear lamina protein lamin A regulating nuclear shape, nuclear mechanics and ultimately gene expression. Defective lamin A expression causes muscle pathologies and premature ageing syndromes, but the roles of nuclear structure and function in physiological ageing and in exercise adaptations remain obscure. Here, we isolated single muscle fibres and carried out detailed morphological and functional analyses on myonuclei from young and older exercise-trained individuals. Strikingly, myonuclei from trained individuals were more spherical, less deformable, and contained a thicker nuclear lamina than those from untrained individuals. Complementary to this, exercise resulted in increased levels of lamin A and increased myonuclear stiffness in mice. We conclude that exercise is associated with myonuclear remodelling, independently of age, which may contribute to the preservative effects of exercise on muscle function throughout the lifespan. KEY POINTS: The nucleus plays an active role in translating forces into biochemical signals. Myonuclear aberrations in a group of muscular dystrophies called laminopathies suggest that the shape and mechanical properties of myonuclei are important for maintaining muscle function. Here, striking differences are presented in myonuclear shape and mechanics associated with exercise, in both young and old humans. Myonuclei from trained individuals were more spherical, less deformable and contained a thicker nuclear lamina than untrained individuals. It is concluded that exercise is associated with age-independent myonuclear remodelling, which may help to maintain muscle function throughout the lifespan.
Collapse
Affiliation(s)
- E Battey
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, King's College London, London, UK
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
| | - J A Ross
- British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, King's College London, London, UK
| | - A Hoang
- British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, King's College London, London, UK
| | - D G S Wilson
- School of Engineering and Materials Science, Queen Mary University of London, London, UK
| | - Y Han
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - Y Levy
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - R D Pollock
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - M Kalakoutis
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- Randall Centre for Cell and Molecular Biophysics, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - J N Pugh
- School of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK
| | - G L Close
- School of Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK
| | - G M Ellison-Hughes
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - N R Lazarus
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - T Iskratsch
- School of Engineering and Materials Science, Queen Mary University of London, London, UK
- Randall Centre for Cell and Molecular Biophysics, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - S D R Harridge
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - J Ochala
- Centre for Human & Applied Physiological Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - M J Stroud
- British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, King's College London, London, UK
| |
Collapse
|
8
|
Kieh M, Richert L, Beavogui AH, Grund B, Leigh B, D'Ortenzio E, Doumbia S, Lhomme E, Sow S, Vatrinet R, Roy C, Kennedy SB, Faye S, Lees S, Millimouno NP, Camara AM, Samai M, Deen GF, Doumbia M, Espérou H, Pierson J, Watson-Jones D, Diallo A, Wentworth D, McLean C, Simon J, Wiedemann A, Dighero-Kemp B, Hensley L, Lane HC, Levy Y, Piot P, Greenwood B, Chêne G, Neaton J, Yazdanpanah Y. Randomized Trial of Vaccines for Zaire Ebola Virus Disease. N Engl J Med 2022; 387:2411-2424. [PMID: 36516078 DOI: 10.1056/nejmoa2200072] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND Questions remain concerning the rapidity of immune responses and the durability and safety of vaccines used to prevent Zaire Ebola virus disease. METHODS We conducted two randomized, placebo-controlled trials - one involving adults and one involving children - to evaluate the safety and immune responses of three vaccine regimens against Zaire Ebola virus disease: Ad26.ZEBOV followed by MVA-BN-Filo 56 days later (the Ad26-MVA group), rVSVΔG-ZEBOV-GP followed by placebo 56 days later (the rVSV group), and rVSVΔG-ZEBOV-GP followed by rVSVΔG-ZEBOV-GP 56 days later (the rVSV-booster group). The primary end point was antibody response at 12 months, defined as having both a 12-month antibody concentration of at least 200 enzyme-linked immunosorbent assay units (EU) per milliliter and an increase from baseline in the antibody concentration by at least a factor of 4. RESULTS A total of 1400 adults and 1401 children underwent randomization. Among both adults and children, the incidence of injection-site reactions and symptoms (e.g., feverishness and headache) was higher in the week after receipt of the primary and second or booster vaccinations than after receipt of placebo but not at later time points. These events were largely low-grade. At month 12, a total of 41% of adults (titer, 401 EU per milliliter) and 78% of children (titer, 828 EU per milliliter) had a response in the Ad26-MVA group; 76% (titer, 992 EU per milliliter) and 87% (titer, 1415 EU per milliliter), respectively, had a response in the rVSV group; 81% (titer, 1037 EU per milliliter) and 93% (titer, 1745 EU per milliliter), respectively, had a response in the rVSV-booster group; and 3% (titer, 93 EU per milliliter) and 4% (titer, 67 EU per milliliter), respectively, had a response in the placebo group (P<0.001 for all comparisons of vaccine with placebo). In both adults and children, antibody responses with vaccine differed from those with placebo beginning on day 14. CONCLUSIONS No safety concerns were identified in this trial. With all three vaccine regimens, immune responses were seen from day 14 through month 12. (Funded by the National Institutes of Health and others; PREVAC ClinicalTrials.gov number, NCT02876328; EudraCT numbers, 2017-001798-18 and 2017-001798-18/3rd; and Pan African Clinical Trials Registry number, PACTR201712002760250.).
Collapse
Affiliation(s)
- Mark Kieh
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Laura Richert
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Abdoul H Beavogui
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Birgit Grund
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Bailah Leigh
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Eric D'Ortenzio
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Seydou Doumbia
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Edouard Lhomme
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Samba Sow
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Renaud Vatrinet
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Céline Roy
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Stephen B Kennedy
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Sylvain Faye
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Shelley Lees
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Niouma P Millimouno
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Alseny M Camara
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Mohamed Samai
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Gibrilla F Deen
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Moussa Doumbia
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Hélène Espérou
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Jerome Pierson
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Deborah Watson-Jones
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Alpha Diallo
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Deborah Wentworth
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Chelsea McLean
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Jakub Simon
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Aurélie Wiedemann
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Bonnie Dighero-Kemp
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Lisa Hensley
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - H Clifford Lane
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Yves Levy
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Peter Piot
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Brian Greenwood
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Geneviève Chêne
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - James Neaton
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| | - Yazdan Yazdanpanah
- From the Partnership for Research on Ebola Virus in Liberia, Monrovia (M.K., S.B.K.); Unité 1219, Bordeaux Population Health, Inria, Statistics in System Biology and Translational Medicine (L.R., E.L.), Euclid-French Clinical Research Infrastructure Network Clinical Trials Platform (L.R., E.L., C.R., G.C.), University of Bordeaux, INSERM, Institut Bergonié, Centre Hospitalier Universitaire de Bordeaux, Clinical Investigation Center-Clinical Epidemiology 1401, Bordeaux (L.R., E.L., C.R., G.C.), INSERM (E.D., R.V., H.E., A.D., A.W., Y.L., Y.Y.), ANRS Emerging Infectious Diseases (France Recherche Nord&Sud Sida-HIV Hépatites) (E.D., A.D., Y.Y.), and Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales (E.D., Y.Y.), Paris, and the Vaccine Research Institute, Université Paris-Est Créteil, Henri Mondor Hospital, Créteil (A.W., Y.L.) - all in France; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Maferinyah, Guinea (A.H.B.); the Schools of Public Health (D.W., J.N.) and Statistics (B. Grund), University of Minnesota, Minneapolis; the College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown (B.L., M.S., G.F.D.); University Clinical Research Center, University of Sciences, Techniques, and Technologies of Bamako (S.D.), and Centre pour le Développement des Vaccins, Ministère de la Santé (M.D.), Bamako, Mali; the Center for Vaccine Development and Global Health, University of Maryland, Baltimore (S.S.), and the National Institute of Allergy and Infectious Diseases, Bethesda (J.P., B.D.-K., L.H., H.C.L.) - both in Maryland; Département de Sociologie, Faculté des Lettres et Sciences Humaines, Université Cheikh Anta Diop (S.F.), and the Alliance for International Medical Action (N.P.M., A.M.C.) - both in Dakar, Senegal; London School of Hygiene and Tropical Medicine, London (S.L., D.W.-J., P.P., B. Greenwood); Janssen Vaccines and Prevention, Leiden, the Netherlands (C.M.); and Merck Sharp and Dohme, Kenilworth, NJ (J.S.)
| |
Collapse
|
9
|
Eliaz D, Paul S, Benyamin D, Cernescu A, Cohen SR, Rosenhek-Goldian I, Brookstein O, Miali ME, Solomonov A, Greenblatt M, Levy Y, Raviv U, Barth A, Shimanovich U. Micro and nano-scale compartments guide the structural transition of silk protein monomers into silk fibers. Nat Commun 2022; 13:7856. [PMID: 36543800 PMCID: PMC9772184 DOI: 10.1038/s41467-022-35505-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Accepted: 12/06/2022] [Indexed: 12/24/2022] Open
Abstract
Silk is a unique, remarkably strong biomaterial made of simple protein building blocks. To date, no synthetic method has come close to reproducing the properties of natural silk, due to the complexity and insufficient understanding of the mechanism of the silk fiber formation. Here, we use a combination of bulk analytical techniques and nanoscale analytical methods, including nano-infrared spectroscopy coupled with atomic force microscopy, to probe the structural characteristics directly, transitions, and evolution of the associated mechanical properties of silk protein species corresponding to the supramolecular phase states inside the silkworm's silk gland. We found that the key step in silk-fiber production is the formation of nanoscale compartments that guide the structural transition of proteins from their native fold into crystalline β-sheets. Remarkably, this process is reversible. Such reversibility enables the remodeling of the final mechanical characteristics of silk materials. These results open a new route for tailoring silk processing for a wide range of new material formats by controlling the structural transitions and self-assembly of the silk protein's supramolecular phases.
Collapse
Affiliation(s)
- D. Eliaz
- grid.13992.300000 0004 0604 7563Department of Molecular Chemistry and Materials Science, Faculty of Chemistry, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - S. Paul
- grid.10548.380000 0004 1936 9377Department of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius väg 16C, 10691 Stockholm, Sweden
| | - D. Benyamin
- grid.9619.70000 0004 1937 0538Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, 9190401 Israel
| | - A. Cernescu
- grid.431971.9Neaspec—Attocube Systems AG, Eglfinger Weg 2, Haar, 85540 Munich Germany
| | - S. R. Cohen
- grid.13992.300000 0004 0604 7563Department of Chemical Research Support, Weizmann Institute of Science, 7610001 Re-hovot, Israel
| | - I. Rosenhek-Goldian
- grid.13992.300000 0004 0604 7563Department of Chemical Research Support, Weizmann Institute of Science, 7610001 Re-hovot, Israel
| | - O. Brookstein
- grid.13992.300000 0004 0604 7563Department of Molecular Chemistry and Materials Science, Faculty of Chemistry, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - M. E. Miali
- grid.13992.300000 0004 0604 7563Department of Molecular Chemistry and Materials Science, Faculty of Chemistry, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - A. Solomonov
- grid.13992.300000 0004 0604 7563Department of Molecular Chemistry and Materials Science, Faculty of Chemistry, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - M. Greenblatt
- grid.13992.300000 0004 0604 7563Department of Chemical and Structural Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - Y. Levy
- grid.13992.300000 0004 0604 7563Department of Chemical and Structural Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel
| | - U. Raviv
- grid.9619.70000 0004 1937 0538Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, 9190401 Israel
| | - A. Barth
- grid.10548.380000 0004 1936 9377Department of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius väg 16C, 10691 Stockholm, Sweden
| | - U. Shimanovich
- grid.13992.300000 0004 0604 7563Department of Molecular Chemistry and Materials Science, Faculty of Chemistry, Weizmann Institute of Science, 7610001 Rehovot, Israel
| |
Collapse
|
10
|
Pastor Y, Ghazzaui N, Hammoudi A, Centlivre M, Cardinaud S, Levy Y. Refining the DC-targeting vaccination for preventing emerging infectious diseases. Front Immunol 2022; 13:949779. [PMID: 36016929 PMCID: PMC9396646 DOI: 10.3389/fimmu.2022.949779] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Accepted: 07/14/2022] [Indexed: 11/26/2022] Open
Abstract
The development of safe, long-term, effective vaccines is still a challenge for many infectious diseases. Thus, the search of new vaccine strategies and production platforms that allow rapidly and effectively responding against emerging or reemerging pathogens has become a priority in the last years. Targeting the antigens directly to dendritic cells (DCs) has emerged as a new approach to enhance the immune response after vaccination. This strategy is based on the fusion of the antigens of choice to monoclonal antibodies directed against specific DC surface receptors such as CD40. Since time is essential, in silico approaches are of high interest to select the most immunogenic and conserved epitopes to improve the T- and B-cells responses. The purpose of this review is to present the advances in DC vaccination, with special focus on DC targeting vaccines and epitope mapping strategies and provide a new framework for improving vaccine responses against infectious diseases.
Collapse
Affiliation(s)
- Yadira Pastor
- Vaccine Research Institute, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, Inserm U955, Team 16, Créteil, France
| | - Nour Ghazzaui
- Vaccine Research Institute, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, Inserm U955, Team 16, Créteil, France
| | - Adele Hammoudi
- Vaccine Research Institute, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, Inserm U955, Team 16, Créteil, France
| | - Mireille Centlivre
- Vaccine Research Institute, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, Inserm U955, Team 16, Créteil, France
| | - Sylvain Cardinaud
- Vaccine Research Institute, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, Inserm U955, Team 16, Créteil, France
| | - Yves Levy
- Vaccine Research Institute, Université Paris-Est Créteil, Institut Mondor de Recherche Biomédicale, Inserm U955, Team 16, Créteil, France
- Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France
- *Correspondence: Yves Levy,
| |
Collapse
|
11
|
Alexandre M, Marlin R, Prague M, Coleon S, Kahlaoui N, Cardinaud S, Naninck T, Delache B, Surenaud M, Galhaut M, Dereuddre-Bosquet N, Cavarelli M, Maisonnasse P, Centlivre M, Lacabaratz C, Wiedemann A, Zurawski S, Zurawski G, Schwartz O, Sanders RW, Le Grand R, Levy Y, Thiébaut R. Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. eLife 2022; 11:75427. [PMID: 35801637 PMCID: PMC9282856 DOI: 10.7554/elife.75427] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 06/22/2022] [Indexed: 11/29/2022] Open
Abstract
The definition of correlates of protection is critical for the development of next-generation SARS-CoV-2 vaccine platforms. Here, we propose a model-based approach for identifying mechanistic correlates of protection based on mathematical modelling of viral dynamics and data mining of immunological markers. The application to three different studies in non-human primates evaluating SARS-CoV-2 vaccines based on CD40-targeting, two-component spike nanoparticle and mRNA 1273 identifies and quantifies two main mechanisms that are a decrease of rate of cell infection and an increase in clearance of infected cells. Inhibition of RBD binding to ACE2 appears to be a robust mechanistic correlate of protection across the three vaccine platforms although not capturing the whole biological vaccine effect. The model shows that RBD/ACE2 binding inhibition represents a strong mechanism of protection which required significant reduction in blocking potency to effectively compromise the control of viral replication.
Collapse
Affiliation(s)
- Marie Alexandre
- Department of Public Health, Inserm Bordeaux Population Health Research Centre, University of Bordeaux, Inria SISTM, UMR 1219, Bordeaux, France
| | - Romain Marlin
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Mélanie Prague
- Department of Public Health, Inserm Bordeaux Population Health Research Centre, University of Bordeaux, Inria SISTM, UMR 1219, Bordeaux, France
| | - Severin Coleon
- Vaccine Research Institute, Inserm U955, Créteil, France
| | - Nidhal Kahlaoui
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | | | - Thibaut Naninck
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Benoit Delache
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | | | - Mathilde Galhaut
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Nathalie Dereuddre-Bosquet
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Mariangela Cavarelli
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Pauline Maisonnasse
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | | | | | | | - Sandra Zurawski
- Baylor Scott and White Research Institute, Dallas, United States
| | - Gerard Zurawski
- Baylor Scott and White Research Institute, Dallas, United States
| | | | - Rogier W Sanders
- Department of Medical Microbiology, University of Amsterdam, Amsterdam, Netherlands
| | - Roger Le Grand
- Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France
| | - Yves Levy
- Vaccine Research Institute, Inserm U955, Créteil, France
| | - Rodolphe Thiébaut
- Department of Public Health, Inserm Bordeaux Population Health Research Centre, University of Bordeaux, Inria SISTM, UMR 1219, Bordeaux, France
| |
Collapse
|
12
|
Wagstaffe HR, Anzala O, Kibuuka H, Anywaine Z, Sirima SB, Thiébaut R, Richert L, Levy Y, Lacabaratz C, Bockstal V, Luhn K, Douoguih M, Goodier MR. NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans. Vaccines (Basel) 2022; 10:vaccines10060884. [PMID: 35746491 PMCID: PMC9230153 DOI: 10.3390/vaccines10060884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 05/26/2022] [Accepted: 05/27/2022] [Indexed: 11/21/2022] Open
Abstract
Natural killer cells play an important role in the control of viral infections both by regulating acquired immune responses and as potent innate or antibody-mediated cytotoxic effector cells. NK cells have been implicated in control of Ebola virus infections and our previous studies in European trial participants have demonstrated durable activation, proliferation and antibody-dependent NK cell activation after heterologous two-dose Ebola vaccination with adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo. Regional variation in immunity and environmental exposure to pathogens, in particular human cytomegalovirus, have profound impacts on NK cell functional capacity. We therefore assessed the NK cell phenotype and function in African trial participants with universal exposure to HCMV. We demonstrate a significant redistribution of NK cell subsets after vaccine dose two, involving the enrichment of less differentiated CD56dimCD57− and CD56dimFcεR1γ+ (canonical) cells and the increased proliferation of these subsets. Sera taken after vaccine dose two support robust antibody-dependent NK cell activation in a standard NK cell readout; these responses correlate strongly with the concentration of anti-Ebola glycoprotein specific antibodies. These sera also promote comparable IFN-γ production in autologous NK cells taken at baseline and post-vaccine dose two. However, degranulation responses of post-vaccination NK cells were reduced compared to baseline NK cells and these effects could not be directly attributed to alterations in NK cell phenotype after vaccination. These studies demonstrate consistent changes in NK cell phenotypic composition and robust antibody-dependent NK cell function and reveal novel characteristics of these responses after heterologous two dose Ebola vaccination in African individuals.
Collapse
Affiliation(s)
- Helen R. Wagstaffe
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK;
- Department of Infectious Disease, Imperial College London, London W2 1PG, UK
| | - Omu Anzala
- KAVI—Institute of Clinical Research University of Nairobi, Nairobi 19676, Kenya;
| | - Hannah Kibuuka
- Makerere University—Walter Reed Project, Kampala 16524, Uganda;
| | - Zacchaeus Anywaine
- Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe P.O. Box 49, Uganda;
| | - Sodiomon B. Sirima
- Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Unité de Recherche Clinique de Banfora, 1487 Avenue Kumda Yonré, Ouagadougou 01 BP 2208, Burkina Faso;
| | - Rodolphe Thiébaut
- Bordeaux Population Health Research Center, University Bordeaux, Inserm, UMR 1219, 33000 Bordeaux, France; (R.T.); (L.R.)
- CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000 Bordeaux, France
- Inria SISTM Team, F-33405 Talence, France
| | - Laura Richert
- Bordeaux Population Health Research Center, University Bordeaux, Inserm, UMR 1219, 33000 Bordeaux, France; (R.T.); (L.R.)
- CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000 Bordeaux, France
- Inria SISTM Team, F-33405 Talence, France
| | - Yves Levy
- Inserm U955, Vaccine Research Institute, Université Paris-Est Créteil, Hôpital Henri Mondor, 94010 Creteil, France; (Y.L.); (C.L.)
| | - Christine Lacabaratz
- Inserm U955, Vaccine Research Institute, Université Paris-Est Créteil, Hôpital Henri Mondor, 94010 Creteil, France; (Y.L.); (C.L.)
| | - Viki Bockstal
- Janssen Vaccines and Prevention, 2333 CP Leiden, The Netherlands; (V.B.); (K.L.); (M.D.)
| | - Kerstin Luhn
- Janssen Vaccines and Prevention, 2333 CP Leiden, The Netherlands; (V.B.); (K.L.); (M.D.)
| | - Macaya Douoguih
- Janssen Vaccines and Prevention, 2333 CP Leiden, The Netherlands; (V.B.); (K.L.); (M.D.)
| | - Martin R. Goodier
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK;
- Flow Cytometry and Immunology Platform, MRC Unit the Gambia at London School of Hygiene and Tropical Medicine, Banjul P.O. Box 273, The Gambia
- Correspondence:
| |
Collapse
|
13
|
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C, Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, de Tejada BM, Marzolini C, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rudin C, Schöni-Affolter F, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Weber R, Yerly S, van der Valk M, Geerlings SE, Goorhuis A, Hovius JW, Lempkes B, Nellen FJB, van der Poll T, Prins JM, Reiss P, van Vugt M, Wiersinga WJ, Wit FWMN, van Duinen M, van Eden J, Hazenberg A, van Hes AMH, Rajamanoharan S, Robinson T, Taylor B, Brewer C, Mayr C, Schmidt W, Speidel A, Strohbach F, Arastéh K, Cordes C, Pijnappel FJJ, Stündel M, Claus J, Baumgarten A, Carganico A, Ingiliz P, Dupke S, Freiwald M, Rausch M, Moll A, Schleehauf D, Smalhout SY, Hintsche B, Klausen G, Jessen H, Jessen A, Köppe S, Kreckel P, Schranz D, Fischer K, Schulbin H, Speer M, Weijsenfeld AM, Glaunsinger T, Wicke T, Bieniek B, Hillenbrand H, Schlote F, Lauenroth-Mai E, Schuler C, Schürmann D, Wesselmann H, Brockmeyer N, Jurriaans S, Gehring P, Schmalöer D, Hower M, Spornraft-Ragaller P, Häussinger D, Reuter S, Esser S, Markus R, Kreft B, Berzow D, Back NKT, Christl A, Meyer A, Plettenberg A, Stoehr A, Graefe K, Lorenzen T, Adam A, Schewe K, Weitner L, Fenske S, Zaaijer HL, Hansen S, Stellbrink HJ, Wiemer D, Hertling S, Schmidt R, Arbter P, Claus B, Galle P, Jäger H, Jä Gel-Guedes E, Berkhout B, Postel N, Fröschl M, Spinner C, Bogner J, Salzberger B, Schölmerich J, Audebert F, Marquardt T, Schaffert A, Schnaitmann E, Cornelissen MTE, Trein A, Frietsch B, Müller M, Ulmer A, Detering-Hübner B, Kern P, Schubert F, Dehn G, Schreiber M, Güler C, Schinkel CJ, Gunsenheimer-Bartmeyer B, Schmidt D, Meixenberger K, Bannert N, Wolthers KC, Peters EJG, van Agtmael MA, Autar RS, Bomers M, Sigaloff KCE, Heitmuller M, Laan LM, Ang CW, van Houdt R, Jonges M, Kuijpers TW, Pajkrt D, Scherpbier HJ, de Boer C, van der Plas A, van den Berge M, Stegeman A, Baas S, Hage de Looff L, Buiting A, Reuwer A, Veenemans J, Wintermans B, Pronk MJH, Ammerlaan HSM, van den Bersselaar DNJ, de Munnik ES, Deiman B, Jansz AR, Scharnhorst V, Tjhie J, Wegdam MCA, van Eeden A, Nellen J, Brokking W, Elsenburg LJM, Nobel H, van Kasteren MEE, Berrevoets MAH, Brouwer AE, Adams A, van Erve R, de Kruijf-van de Wiel BAFM, Keelan-Phaf S, van de Ven B, van der Ven B, Buiting AGM, Murck JL, de Vries-Sluijs TEMS, Bax HI, van Gorp ECM, de Jong-Peltenburg NC, de Mendonç A Melo M, van Nood E, Nouwen JL, Rijnders BJA, Rokx C, Schurink CAM, Slobbe L, Verbon A, Bassant N, van Beek JEA, Vriesde M, van Zonneveld LM, de Groot J, Boucher CAB, Koopmans MPG, van Kampen JJA, Fraaij PLA, van Rossum AMC, Vermont CL, van der Knaap LC, Visser E, Branger J, Douma RA, Cents-Bosma AS, Duijf-van de Ven CJHM, Schippers EF, van Nieuwkoop C, van Ijperen JM, Geilings J, van der Hut G, van Burgel ND, Leyten EMS, Gelinck LBS, Mollema F, Davids-Veldhuis S, Tearno C, Wildenbeest GS, Heikens E, Groeneveld PHP, Bouwhuis JW, Lammers AJJ, Kraan S, van Hulzen AGW, Kruiper MSM, van der Bliek GL, Bor PCJ, Debast SB, Wagenvoort GHJ, Kroon FP, de Boer MGJ, Jolink H, Lambregts MMC, Roukens AHE, Scheper H, Dorama W, van Holten N, Claas ECJ, Wessels E, den Hollander JG, El Moussaoui R, Pogany K, Brouwer CJ, Smit JV, Struik-Kalkman D, van Niekerk T, Pontesilli O, Lowe SH, Oude Lashof AML, Posthouwer D, van Wolfswinkel ME, Ackens RP, Burgers K, Schippers J, Weijenberg-Maes B, van Loo IHM, Havenith TRA, van Vonderen MGA, Kampschreur LM, Faber S, Steeman-Bouma R, Al Moujahid A, Kootstra GJ, Delsing CE, van der Burg-van de Plas M, Scheiberlich L, Kortmann W, van Twillert G, Renckens R, Ruiter-Pronk D, van Truijen-Oud FA, Cohen Stuart JWT, Jansen ER, Hoogewerf M, Rozemeijer W, van der Reijden WA, Sinnige JC, Brinkman K, van den Berk GEL, Blok WL, Lettinga KD, de Regt M, Schouten WEM, Stalenhoef JE, Veenstra J, Vrouenraets SME, Blaauw H, Geerders GF, Kleene MJ, Kok M, Knapen M, van der Meché IB, Mulder-Seeleman E, Toonen AJM, Wijnands S, Wttewaal E, Kwa D, van Crevel R, van Aerde K, Dofferhoff ASM, Henriet SSV, Ter Hofstede HJM, Hoogerwerf J, Keuter M, Richel O, Albers M, Grintjes-Huisman KJT, de Haan M, Marneef M, Strik-Albers R, Rahamat-Langendoen J, Stelma FF, Burger D, Gisolf EH, Hassing RJ, Claassen M, Ter Beest G, van Bentum PHM, Langebeek N, Tiemessen R, Swanink CMA, van Lelyveld SFL, Soetekouw R, van der Prijt LMM, van der Swaluw J, Bermon N, van der Reijden WA, Jansen R, Herpers BL, Veenendaal D, Verhagen DWM, Lauw FN, van Broekhuizen MC, van Wijk M, Bierman WFW, Bakker M, Kleinnijenhuis J, Kloeze E, Middel A, Postma DF, Schölvinck EH, Stienstra Y, Verhage AR, Wouthuyzen-Bakker M, Boonstra A, de Groot-de Jonge H, van der Meulen PA, de Weerd DA, Niesters HGM, van Leer-Buter CC, Knoester M, Hoepelman AIM, Arends JE, Barth RE, Bruns AHW, Ellerbroek PM, Mudrikova T, Oosterheert JJ, Schadd EM, van Welzen BJ, Aarsman K, Griffioen-van Santen BMG, de Kroon I, van Berkel M, van Rooijen CSAM, Schuurman R, Verduyn-Lunel F, Wensing AMJ, Bont LJ, Geelen SPM, Loeffen YGT, Wolfs TFW, Nauta N, Rooijakkers EOW, Holtsema H, Voigt R, van de Wetering D, Alberto A, van der Meer I, Rosingh A, Halaby T, Zaheri S, Boyd AC, Bezemer DO, van Sighem AI, Smit C, Hillebregt M, de Jong A, Woudstra T, Bergsma D, Meijering R, van de Sande L, Rutkens T, van der Vliet S, de Groot L, van den Akker M, Bakker Y, El Berkaoui A, Bezemer M, Brétin N, Djoechro E, Groters M, Kruijne E, Lelivelt KJ, Lodewijk C, Lucas E, Munjishvili L, Paling F, Peeck B, Ree C, Regtop R, Ruijs Y, Schoorl M, Schnörr P, Scheigrond A, Tuijn E, Veenenberg L, Visser KM, Witte EC, Ruijs Y, Van Frankenhuijsen M, Allegre T, Makhloufi D, Livrozet JM, Chiarello P, Godinot M, Brunel-Dalmas F, Gibert S, Trepo C, Peyramond D, Miailhes P, Koffi J, Thoirain V, Brochier C, Baudry T, Pailhes S, Lafeuillade A, Philip G, Hittinger G, Assi A, Lambry V, Rosenthal E, Naqvi A, Dunais B, Cua E, Pradier C, Durant J, Joulie A, Quinsat D, Tempesta S, Ravaux I, Martin IP, Faucher O, Cloarec N, Champagne H, Pichancourt G, Morlat P, Pistone T, Bonnet F, Mercie P, Faure I, Hessamfar M, Malvy D, Lacoste D, Pertusa MC, Vandenhende MA, Bernard N, Paccalin F, Martell C, Roger-Schmelz J, Receveur MC, Duffau P, Dondia D, Ribeiro E, Caltado S, Neau D, Dupont M, Dutronc H, Dauchy F, Cazanave C, Vareil MO, Wirth G, Le Puil S, Pellegrin JL, Raymond I, Viallard JF, Chaigne de Lalande S, Garipuy D, Delobel P, Obadia M, Cuzin L, Alvarez M, Biezunski N, Porte L, Massip P, Debard A, Balsarin F, Lagarrigue M, Prevoteau du Clary F, Aquilina C, Reynes J, Baillat V, Merle C, Lemoing V, Atoui N, Makinson A, Jacquet JM, Psomas C, Tramoni C, Aumaitre H, Saada M, Medus M, Malet M, Eden A, Neuville S, Ferreyra M, Sotto A, Barbuat C, Rouanet I, Leureillard D, Mauboussin JM, Lechiche C, Donsesco R, Cabie A, Abel S, Pierre-Francois S, Batala AS, Cerland C, Rangom C, Theresine N, Hoen B, Lamaury I, Fabre I, Schepers K, Curlier E, Ouissa R, Gaud C, Ricaud C, Rodet R, Wartel G, Sautron C, Beck-Wirth G, Michel C, Beck C, Halna JM, Kowalczyk J, Benomar M, Drobacheff-Thiebaut C, Chirouze C, Faucher JF, Parcelier F, Foltzer A, Haffner-Mauvais C, Hustache Mathieu M, Proust A, Piroth L, Chavanet P, Duong M, Buisson M, Waldner A, Mahy S, Gohier S, Croisier D, May T, Delestan M, Andre M, Zadeh MM, Martinot M, Rosolen B, Pachart A, Martha B, Jeunet N, Rey D, Cheneau C, Partisani M, Priester M, Bernard-Henry C, Batard ML, Fischer P, Berger JL, Kmiec I, Robineau O, Huleux T, Ajana F, Alcaraz I, Allienne C, Baclet V, Meybeck A, Valette M, Viget N, Aissi E, Biekre R, Cornavin P, Merrien D, Seghezzi JC, Machado M, Diab G, Raffi F, Bonnet B, Allavena C, Grossi O, Reliquet V, Billaud E, Brunet C, Bouchez S, Morineau-Le Houssine P, Sauser F, Boutoille D, Besnier M, Hue H, Hall N, Brosseau D, Souala F, Michelet C, Tattevin P, Arvieux C, Revest M, Leroy H, Chapplain JM, Dupont M, Fily F, Patra-Delo S, Lefeuvre C, Bernard L, Bastides F, Nau P, Verdon R, de la Blanchardiere A, Martin A, Feret P, Geffray L, Daniel C, Rohan J, Fialaire P, Chennebault JM, Rabier V, Abgueguen P, Rehaiem S, Luycx O, Niault M, Moreau P, Poinsignon Y, Goussef M, Mouton-Rioux V, Houlbert D, Alvarez-Huve S, Barbe F, Haret S, Perre P, Leantez-Nainville S, Esnault JL, Guimard T, Suaud I, Girard JJ, Simonet V, Debab Y, Schmit JL, Jacomet C, Weinberck P, Genet C, Pinet P, Ducroix S, Durox H, Denes É, Abraham B, Gourdon F, Antoniotti O, Molina JM, Ferret S, Lascoux-Combe C, Lafaurie M, Colin de Verdiere N, Ponscarme D, De Castro N, Aslan A, Rozenbaum W, Pintado C, Clavel F, Taulera O, Gatey C, Munier AL, Gazaigne S, Penot P, Conort G, Lerolle N, Leplatois A, Balausine S, Delgado J, Timsit J, Tabet M, Gerard L, Girard PM, Picard O, Tredup J, Bollens D, Valin N, Campa P, Bottero J, Lefebvre B, Tourneur M, Fonquernie L, Wemmert C, Lagneau JL, Yazdanpanah Y, Phung B, Pinto A, Vallois D, Cabras O, Louni F, Pialoux G, Lyavanc T, Berrebi V, Chas J, Lenagat S, Rami A, Diemer M, Parrinello M, Depond A, Salmon D, Guillevin L, Tahi T, Belarbi L, Loulergue P, Zak Dit Zbar O, Launay O, Silbermann B, Leport C, Alagna L, Pietri MP, Simon A, Bonmarchand M, Amirat N, Pichon F, Kirstetter M, Katlama C, Valantin MA, Tubiana R, Caby F, Schneider L, Ktorza N, Calin R, Merlet A, Ben Abdallah S, Weiss L, Buisson M, Batisse D, Karmochine M, Pavie J, Minozzi C, Jayle D, Castel P, Derouineau J, Kousignan P, Eliazevitch M, Pierre I, Collias L, Viard JP, Gilquin J, Sobel A, Slama L, Ghosn J, Hadacek B, Thu-Huyn N, Nait-Ighil L, Cros A, Maignan A, Duvivier C, Consigny PH, Lanternier F, Shoai-Tehrani M, Touam F, Jerbi S, Bodard L, Jung C, Goujard C, Quertainmont Y, Duracinsky M, Segeral O, Blanc A, Peretti D, Cheret A, Chantalat C, Dulucq MJ, Levy Y, Lelievre JD, Lascaux AS, Dumont C, Boue F, Chambrin V, Abgrall S, Kansau I, Raho-Moussa M, De Truchis P, Dinh A, Davido B, Marigot D, Berthe H, Devidas A, Chevojon P, Chabrol A, Agher N, Lemercier Y, Chaix F, Turpault I, Bouchaud O, Honore P, Rouveix E, Reimann E, Belan AG, Godin Collet C, Souak S, Mortier E, Bloch M, Simonpoli AM, Manceron V, Cahitte I, Hiraux E, Lafon E, Cordonnier F, Zeng AF, Zucman D, Majerholc C, Bornarel D, Uludag A, Gellen-Dautremer J, Lefort A, Bazin C, Daneluzzi V, Gerbe J, Jeantils V, Coupard M, Patey O, Bantsimba J, Delllion S, Paz PC, Cazenave B, Richier L, Garrait V, Delacroix I, Elharrar B, Vittecoq D, Bolliot C, Lepretre A, Genet P, Masse V, Perrone V, Boussard JL, Chardon P, Froguel E, Simon P, Tassi S, Avettand Fenoel V, Barin F, Bourgeois C, Cardon F, Chaix ML, Delfraissy JF, Essat A, Fischer H, Lecuroux C, Meyer L, Petrov-Sanchez V, Rouzioux C, Saez-Cirion A, Seng R, Kuldanek K, Mullaney S, Young C, Zucchetti A, Bevan MA, McKernan S, Wandolo E, Richardson C, Youssef E, Green P, Faulkner S, Faville R, Herman S, Care C, Blackman H, Bellenger K, Fairbrother K, Phillips A, Babiker A, Delpech V, Fidler S, Clarke M, Fox J, Gilson R, Goldberg D, Hawkins D, Johnson A, Johnson M, McLean K, Nastouli E, Post F, Kennedy N, Pritchard J, Andrady U, Rajda N, Donnelly C, McKernan S, Drake S, Gilleran G, White D, Ross J, Harding J, Faville R, Sweeney J, Flegg P, Toomer S, Wilding H, Woodward R, Dean G, Richardson C, Perry N, Gompels M, Jennings L, Bansaal D, Browing M, Connolly L, Stanley B, Estreich S, Magdy A, O'Mahony C, Fraser P, Jebakumar SPR, David L, Mette R, Summerfield H, Evans M, White C, Robertson R, Lean C, Morris S, Winter A, Faulkner S, Goorney B, Howard L, Fairley I, Stemp C, Short L, Gomez M, Young F, Roberts M, Green S, Sivakumar K, Minton J, Siminoni A, Calderwood J, Greenhough D, DeSouza C, Muthern L, Orkin C, Murphy S, Truvedi M, McLean K, Hawkins D, Higgs C, Moyes A, Antonucci S, McCormack S, Lynn W, Bevan M, Fox J, Teague A, Anderson J, Mguni S, Post F, Campbell L, Mazhude C, Russell H, Gilson R, Carrick G, Ainsworth J, Waters A, Byrne P, Johnson M, Fidler S, Kuldanek K, Mullaney S, Lawlor V, Melville R, Sukthankar A, Thorpe S, Murphy C, Wilkins E, Ahmad S, Green P, Tayal S, Ong E, Meaden J, Riddell L, Loay D, Peacock K, Blackman H, Harindra V, Saeed AM, Allen S, Natarajan U, Williams O, Lacey H, Care C, Bowman C, Herman S, Devendra SV, Wither J, Bridgwood A, Singh G, Bushby S, Kellock D, Young S, Rooney G, Snart B, Currie J, Fitzgerald M, Arumainayyagam J, Chandramani S. A highly virulent variant of HIV-1 circulating in the Netherlands. Science 2022; 375:540-545. [PMID: 35113714 DOI: 10.1126/science.abk1688] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.
Collapse
Affiliation(s)
- Chris Wymant
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | | | - François Blanquart
- Centre for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, PSL Research University, Paris, France.,IAME, UMR 1137, INSERM, Université de Paris, Paris, France
| | - Luca Ferretti
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Astrid Gall
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
| | - Matthew Hall
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Tanya Golubchik
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Margreet Bakker
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Swee Hoe Ong
- Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK
| | - Lele Zhao
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - David Bonsall
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Mariateresa de Cesare
- Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - George MacIntyre-Cockett
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Lucie Abeler-Dörner
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Jan Albert
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.,Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
| | - Norbert Bannert
- Division for HIV and Other Retroviruses, Department of Infectious Diseases, Robert Koch Institute, Berlin, Germany
| | - Jacques Fellay
- School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.,Swiss Institute of Bioinformatics, Lausanne, Switzerland.,Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - M Kate Grabowski
- Department of Pathology, John Hopkins University, Baltimore, MD, USA
| | | | - Huldrych F Günthard
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.,Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | - Pia Kivelä
- Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland
| | - Roger D Kouyos
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.,Institute of Medical Virology, University of Zurich, Zurich, Switzerland
| | | | - Laurence Meyer
- INSERM CESP U1018, Université Paris Saclay, APHP, Service de Santé Publique, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
| | - Kholoud Porter
- Institute for Global Health, University College London, London, UK
| | - Matti Ristola
- Department of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland
| | | | - Ben Berkhout
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Paul Kellam
- Kymab Ltd., Cambridge, UK.,Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK
| | - Marion Cornelissen
- Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.,Molecular Diagnostic Unit, Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
| | - Peter Reiss
- Stichting HIV Monitoring, Amsterdam, Netherlands.,Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
| | - Christophe Fraser
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Deplanque D, Cviklinski S, Bardou M, Ader F, Blanchard H, Barthélémy P, David I, D'Ortenzio E, Espérou H, Launay O, Lazarevic M, Lechat P, Lethiec F, Levy Y, Pérol D, Rage V, Roustit M, Thabut G. Health crisis: What opportunities for clinical drug research? Therapie 2022; 77:59-67. [PMID: 34973823 PMCID: PMC8673948 DOI: 10.1016/j.therap.2021.12.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 11/23/2021] [Indexed: 12/15/2022]
Abstract
The COVID-19 pandemic led to the deployment of an unprecedented academic and industrial research effort, the sometimes redundant nature of which is regrettable, as is the lack of both national and international management. However, it must be noted that during this crisis, regulatory procedures were adapted and certain obstacles in the organisation of clinical research were partly removed to contribute to the deployment of trials as close as possible to patients and to facilitate monitoring and control procedures. The digitisation of certain processes and the decentralisation of certain activities were implemented under the cover of a mobilisation of the authorities and all institutional, academic and industrial players. While in the UK, the optimisation of resources through a single platform trial has made it possible to demonstrate or invalidate the efficacy of many treatments, in France the health crisis has highlighted the fragility of the organisation of clinical research, in particular a lack of coordination and funding, difficulties in implementing studies and a certain reluctance to share data. However, the crisis has also revealed the adaptability of the various stakeholders and has led to the improvement of several processes useful for the deployment of therapeutic innovation. Let us hope that the lessons learned during this crisis will allow for greater efficiency in the event of a new pandemic and, above all, that the progress made will continue to apply to all future clinical research activities.
Collapse
Affiliation(s)
- Dominique Deplanque
- Inserm, CIC 1403 - centre d'investigation clinique, University Lille, CHU de Lille, 59000 Lille, France.
| | - Stanislas Cviklinski
- Roche SAS - Direction des opérations cliniques, 92100 Boulogne-Billancourt, France
| | - Marc Bardou
- Cellule interministérielle recherche, direction générale de la santé, ministère des Solidarités et de la Santé, 75350 Paris 07 SP, France
| | - Florence Ader
- Département des maladies infectieuses et tropicales, hôpital de la Croix-Rousse, hospices civils de Lyon, 69004 Lyon, France
| | | | | | - Isabelle David
- Sanofi Clinical Study Unit, 91385 Chilly-Mazarin, France
| | - Eric D'Ortenzio
- Inserm ANRS - Maladies infectieuses émergentes, université de Paris - Inserm Infection, Antimicrobien, Modélisation, Evolution (IAME), AP-HP Hôpital Bichat, service de maladies infectieuses et tropicales, Paris, France
| | - Hélène Espérou
- Inserm, pôle de recherche clinique, institut de santé publique, 75013 Paris, France
| | - Odile Launay
- Inserm CIC 1417, F-CRIN, COVIREIVAC, AP-HP, hôpital Cochin, 75014 Paris, France
| | | | | | | | - Yves Levy
- Inserm U955, Team 16, faculté de médecine, Vaccine Research Institute, université Paris-Est Créteil, 94000 Créteil, France
| | - David Pérol
- Direction de la recherche clinique et de l'innovation, centre Léon-Bérard, 69008 Lyon, France
| | - Virginie Rage
- Laboratoire de droit et économie de la santé, faculté de pharmacie, 34093 Montpellier, France
| | - Matthieu Roustit
- Inserm CIC1406, University Grenoble Alpes, CHU de Grenoble, 38000 Grenoble, France
| | | |
Collapse
|
15
|
Ceglia V, Kelley EJ, Boyle AS, Zurawski S, Mead HL, Harms CE, Blanck JP, Flamar AL, Kirschman JH, Ogongo P, Ernst JD, Levy Y, Zurawski G, Altin JA. A Framework to Identify Antigen-Expanded T Cell Receptor Clusters Within Complex Repertoires. Front Immunol 2021; 12:735584. [PMID: 34917073 PMCID: PMC8670329 DOI: 10.3389/fimmu.2021.735584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Accepted: 11/01/2021] [Indexed: 11/13/2022] Open
Abstract
Common approaches for monitoring T cell responses are limited in their multiplexity and sensitivity. In contrast, deep sequencing of the T Cell Receptor (TCR) repertoire provides a global view that is limited only in terms of theoretical sensitivity due to the depth of available sampling; however, the assignment of antigen specificities within TCR repertoires has become a bottleneck. This study combines antigen-driven expansion, deep TCR sequencing, and a novel analysis framework to show that homologous ‘Clusters of Expanded TCRs (CETs)’ can be confidently identified without cell isolation, and assigned to antigen against a background of non-specific clones. We show that clonotypes within each CET respond to the same epitope, and that protein antigens stimulate multiple CETs reactive to constituent peptides. Finally, we demonstrate the personalized assignment of antigen-specificity to rare clones within fully-diverse uncultured repertoires. The method presented here may be used to monitor T cell responses to vaccination and immunotherapy with high fidelity.
Collapse
Affiliation(s)
- Valentina Ceglia
- Baylor Institute for Immunology Research, Dallas, TX, United States.,Université Paris-Est Créteil, Sciences de la Vie et de la Santé, Créteil, France.,Vaccine Research Institute, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - Erin J Kelley
- Translational Genomics Research Institute, Flagstaff, AZ, United States
| | - Annalee S Boyle
- Translational Genomics Research Institute, Flagstaff, AZ, United States
| | - Sandra Zurawski
- Baylor Institute for Immunology Research, Dallas, TX, United States.,Vaccine Research Institute, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - Heather L Mead
- Translational Genomics Research Institute, Flagstaff, AZ, United States
| | - Caroline E Harms
- Translational Genomics Research Institute, Flagstaff, AZ, United States
| | | | - Anne-Laure Flamar
- Baylor Institute for Immunology Research, Dallas, TX, United States.,Université Paris-Est Créteil, Sciences de la Vie et de la Santé, Créteil, France.,Vaccine Research Institute, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France
| | | | - Paul Ogongo
- Department of Medicine, Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States
| | - Joel D Ernst
- Department of Medicine, Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, United States
| | - Yves Levy
- Université Paris-Est Créteil, Sciences de la Vie et de la Santé, Créteil, France.,Vaccine Research Institute, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - Gerard Zurawski
- Baylor Institute for Immunology Research, Dallas, TX, United States.,Vaccine Research Institute, INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France
| | - John A Altin
- Translational Genomics Research Institute, Flagstaff, AZ, United States
| |
Collapse
|
16
|
Deplanque D, Cviklinski S, Bardou M, Ader F, Blanchard H, Barthélemy P, David I, D'Ortenzio E, Espérou H, Launay O, Lazarevic M, Lechat P, Lethiec F, Levy Y, Pérol D, Rage V, Roustit M, Thabut G. Crise sanitaire : quelles opportunités pour la recherche clinique sur le médicament ? Therapie 2021; 77:49-57. [PMID: 34924206 PMCID: PMC8648377 DOI: 10.1016/j.therap.2021.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 11/23/2021] [Indexed: 12/15/2022]
Abstract
La pandémie de coronavirus disease-19 (COVID-19) a conduit au déploiement d’un effort de recherche académique et industriel sans précédent dont on peut regretter le caractère parfois redondant ainsi que le manque de pilotage tant national qu’international. Pourtant, force est de constater qu’à l’occasion de cette crise, les procédures réglementaires ont été adaptées de même que certains freins dans l’organisation de la recherche clinique ont pu être en partie levés pour contribuer au déploiement d’essais au plus près des patients et faciliter les modalités de suivi et de contrôle. La digitalisation de certains processus et la décentralisation de certaines activités ont pu être mises en œuvre sous couvert d’une mobilisation des autorités et de l’ensemble des acteurs institutionnels, académiques ou industriels. Si outre-manche, l’optimisation des ressources, au travers d’un essai de plateforme unique, a permis de montrer ou d’infirmer l’efficacité de nombreux traitements, en France la crise sanitaire a mis en lumière la fragilité de l’organisation de la recherche clinique, notamment un déficit de coordination et de financement, des difficultés dans la mise en œuvre des études ou encore une certaine frilosité concernant le partage des données. Cependant, la crise a aussi révélé les capacités d’adaptation des différents acteurs et permis l’amélioration de plusieurs processus utiles au déploiement de l’innovation thérapeutique. Gageons que les leçons tirées à l’occasion de cette crise permettront une meilleure efficacité en cas de nouvelle pandémie et surtout que les progrès obtenus continueront de s’appliquer à l’ensemble des activités de recherche clinique futures.
Collapse
Affiliation(s)
- Dominique Deplanque
- University Lille, Inserm, CHU Lille, CIC 1403 - Centre d'investigation clinique, 59000 Lille, France.
| | - Stanislas Cviklinski
- Roche SAS - Direction des opérations cliniques, 92100 Boulogne-Billancourt, France
| | - Marc Bardou
- Cellule interministérielle recherche, direction générale de la santé, ministère des Solidarités et de la Santé, 75350 Paris 07 SP, France
| | - Florence Ader
- Département des maladies infectieuses et tropicales, hôpital de la Croix-Rousse, Hospices civils de Lyon, 69004 Lyon, France
| | | | | | - Isabelle David
- Sanofi Clinical Study Unit, 91385 Chilly-Mazarin, France
| | - Eric D'Ortenzio
- Université de Paris, Inserm CIC 1417, Assistance publique - Hôpitaux de Paris, hôpital Cochin, 75014 Paris, France
| | - Hélène Espérou
- Pôle de recherche clinique, institut de santé publique, INSERM, 75013 Paris, France
| | - Odile Launay
- Inserm CIC 1417, F-CRIN, COVIREIVAC, Assistance publique - hôpitaux de Paris, hôpital Cochin, 75014 Paris, France
| | | | - Philippe Lechat
- Université de Paris, Assistance publique - hôpitaux de Paris, AGEPS, 75005 Paris, France
| | | | - Yves Levy
- Vaccine Research Institute, université Paris-Est Créteil, faculté de médecine, INSERM U955, Team 16, 94000 Créteil, France
| | - David Pérol
- Direction de la recherche clinique et de l'innovation, centre Léon Bérard, 69008 Lyon, France
| | - Virginie Rage
- Faculté de pharmacie, laboratoire de droit et économie de la santé, 34093 Montpellier, France
| | - Matthieu Roustit
- University Grenoble Alpes, CHU de Grenoble, Inserm CIC1406, 38000 Grenoble, France
| | | |
Collapse
|
17
|
Abbas A, Abdukahil SA, Abdulkadir NN, Abe R, Abel L, Absil L, Acharya S, Acker A, Adachi S, Adam E, Adrião D, Ageel SA, Ahmed S, Ain Q, Ainscough K, Aisa T, Ait Hssain A, Ait Tamlihat Y, Akimoto T, Akmal E, Al Qasim E, Alalqam R, Alam T, Al-dabbous T, Alegesan S, Alegre C, Alessi M, Alex B, Alexandre K, Al-Fares A, Alfoudri H, Ali I, Ali Shah N, Alidjnou KE, Aliudin J, Alkhafajee Q, Allavena C, Allou N, Altaf A, Alves J, Alves JM, Alves R, Amaral M, Amira N, Ammerlaan H, Ampaw P, Andini R, Andrejak C, Angheben A, Angoulvant F, Ansart S, Anthonidass S, Antonelli M, Antunes de Brito CA, Anwar KR, Apriyana A, Arabi Y, Aragao I, Arali R, Arancibia F, Araujo C, Arcadipane A, Archambault P, Arenz L, Arlet JB, Arnold-Day C, Aroca A, Arora L, Arora R, Artaud-Macari E, Aryal D, Asaki M, Asensio A, Ashley E, Ashraf M, Ashraf S, Asim M, Assie JB, Asyraf A, Atique A, Attanyake AMUL, Auchabie J, Aumaitre H, Auvet A, Azemar L, Azoulay C, Bach B, Bachelet D, Badr C, Baig N, Baillie JK, Baird JK, Bak E, Bakakos A, Bakar NA, Bal A, Balakrishnan M, Balan V, Bani-Sadr F, Barbalho R, Barbosa NY, Barclay WS, Barnett SU, Barnikel M, Barrasa H, Barrelet A, Barrigoto C, Bartoli M, Bartone C, Baruch J, Bashir M, Basmaci R, Basri MFH, Bastos D, Battaglini D, Bauer J, Bautista Rincon DF, Bazan Dow D, Bedossa A, Bee KH, Behilill S, Beishuizen A, Beljantsev A, Bellemare D, Beltrame A, Beltrão BA, Beluze M, Benech N, Benjiman LE, Benkerrou D, Bennett S, Bento L, Berdal JE, Bergeaud D, Bergin H, Bernal Sobrino JL, Bertoli G, Bertolino L, Bessis S, Betz A, Bevilcaqua S, Bezulier K, Bhatt A, Bhavsar K, Bianchi I, Bianco C, Bidin FN, Bikram Singh M, Bin Humaid F, Bin Kamarudin MN, Bissuel F, Biston P, Bitker L, Blanco-Schweizer P, Blier C, Bloos F, Blot M, Blumberg L, Boccia F, Bodenes L, Bogaarts A, Bogaert D, Boivin AH, Bolze PA, Bompart F, Bonfasius A, Borges D, Borie R, Bosse HM, Botelho-Nevers E, Bouadma L, Bouchaud O, Bouchez S, Bouhmani D, Bouhour D, Bouiller K, Bouillet L, Bouisse C, Boureau AS, Bourke J, Bouscambert M, Bousquet A, Bouziotis J, Boxma B, Boyer-Besseyre M, Boylan M, Bozza FA, Brack M, Braconnier A, Braga C, Brandenburger T, Brás Monteiro F, Brazzi L, Breen D, Breen P, Breen P, Brett S, Brickell K, Broadley T, Browne A, Browne S, Brozzi N, Brusse-Keizer M, Buchtele N, Buesaquillo C, Bugaeva P, Buisson M, Burhan E, Burrell A, Bustos IG, Butnaru D, Cabie A, Cabral S, Caceres E, Cadoz C, Callahan M, Calligy K, Calvache JA, Cam J, Campana V, Campbell P, Campisi J, Canepa C, Cantero M, Caraux-Paz P, Cárcel S, Cardellino CS, Cardoso F, Cardoso F, Cardoso N, Cardoso S, Carelli S, Carlier N, Carmoi T, Carney G, Carpenter C, Carqueja I, Carret MC, Carrier FM, Carroll I, Carson G, Carton E, Casanova ML, Cascão M, Casey S, Casimiro J, Cassandra B, Castañeda S, Castanheira N, Castor-Alexandre G, Castrillón H, Castro I, Catarino A, Catherine FX, Cattaneo P, Cavalin R, Cavalli GG, Cavayas A, Ceccato A, Cervantes-Gonzalez M, Chair A, Chakveatze C, Chan A, Chand M, Chantalat Auger C, Chapplain JM, Chas J, Chaudary M, Chávez Iñiguez JS, Chen A, Chen YS, Cheng MP, Cheret A, Chiarabini T, Chica J, Chidambaram SK, Chin-Tho L, Chirouze C, Chiumello D, Cho HJ, Cho SM, Cholley B, Chopin MC, Chow TS, Chow YP, Chua HJ, Chua J, Cidade JP, Cisneros Herreros JM, Citarella BW, Ciullo A, Clarke E, Clarke J, Claure Del Granado R, Clohisey S, Cobb JP, Coca N, Codan C, Cody C, Coelho A, Coles M, Colin G, Collins M, Colombo SM, Combs P, Connolly J, Connor M, Conrad A, Contreras S, Conway E, Cooke GS, Copland M, Cordel H, Corley A, Cormican S, Cornelis S, Cornet AD, Corpuz AJ, Cortegiani A, Corvaisier G, Costigan E, Couffignal C, Couffin-Cadiergues S, Courtois R, Cousse S, Cregan R, Crepy D'Orleans C, Croonen S, Crowl G, Crump J, Cruz C, Cruz Berm JL, Cruz Rojo J, Csete M, Cucino A, Cullen A, Cullen C, Cummings M, Curley G, Curlier E, Curran C, Custodio P, da Silva Filipe A, Da Silveira C, Dabaliz AA, Dagens A, Dahly D, Dalton H, Dalton J, Daly S, D'Amico F, Daneman N, Daniel C, Dankwa EA, Dantas J, D’Aragon F, de Boer M, de Loughry G, de Mendoza D, De Montmollin E, de Oliveira França RF, de Pinho Oliveira AI, De Rosa R, de Silva T, de Vries P, Deacon J, Dean D, Debard A, DeBenedictis B, Debray MP, DeCastro N, Dechert W, Deconninck L, Decours R, Defous E, Delacroix I, Delaveuve E, Delavigne K, Delfos NM, Deligiannis I, Dell'Amore A, Delmas C, Delobel P, Delsing C, Demonchy E, Denis E, Deplanque D, Depuydt P, Desai M, Descamps D, Desvallée M, Dewayanti S, Diallo A, Diamantis S, Dias A, Diaz P, Diaz R, Diaz Diaz JJ, Didier K, Diehl JL, Dieperink W, Dimet J, Dinot V, Diop F, Diouf A, Dishon Y, Dixit D, Djossou F, Docherty AB, Doherty H, Dondorp AM, Dong A, Donnelly CA, Donnelly M, Donohue C, Donohue S, Donohue Y, Doran C, Doran P, Dorival C, D'Ortenzio E, Douglas JJ, Douma R, Dournon N, Downer T, Downey J, Downing M, Drake T, Driscoll A, Dryden M, Duarte Fonseca C, Dubee V, Dubos F, Ducancelle A, Duculan T, Dudman S, Duggal A, Dunand P, Dunning J, Duplaix M, Durante-Mangoni E, Durham III L, Dussol B, Duthoit J, Duval X, Dyrhol-Riise AM, Ean SC, Echeverria-Villalobos M, Egan S, Eira C, El Sanharawi M, Elapavaluru S, Elharrar B, Ellerbroek J, Eloy P, Elshazly T, Elyazar I, Enderle I, Endo T, Eng CC, Engelmann I, Enouf V, Epaulard O, Escher M, Esperatti M, Esperou H, Esposito-Farese M, Estevão J, Etienne M, Ettalhaoui N, Everding AG, Evers M, Fabre I, Fabre M, Faheem A, Fahy A, Fairfield CJ, Fakar Z, Faria P, Farooq A, Farrar JJ, Farshait N, Fateena H, Fatoni AZ, Faure K, Favory R, Fayed M, Feely N, Feeney L, Fernandes J, Fernandes M, Fernandes S, Ferrand FX, Ferrand Devouge E, Ferrão J, Ferraz M, Ferreira B, Ferreira S, Ferrer-Roca R, Ferriere N, Ficko C, Figueiredo-Mello C, Fiorda J, Flament T, Flateau C, Fletcher T, Florio LL, Flynn B, Flynn D, Foley C, Foley J, Fomin V, Fonseca T, Fontela P, Forsyth S, Foster D, Foti G, Fourn E, Fowler RA, Fraher DM, Franch-Llasat D, Fraser C, Fraser JF, Freire MV, Freitas Ribeiro A, Friedrich C, Fritz R, Fry S, Fuentes N, Fukuda M, Gaborieau V, Gaci R, Gagliardi M, Gagnard JC, Gagné N, Gagneux-Brunon A, Gaião S, Gail Skeie L, Gallagher P, Gallego Curto E, Gamble C, Gani Y, Garan A, Garcia R, García Barrio N, Garcia-Diaz J, Garcia-Gallo E, Garimella N, Garot D, Garrait V, Gauli B, Gault N, Gavin A, Gavrylov A, Gaymard A, Gebauer J, Geraud E, Gerbaud Morlaes L, Germano N, ghisulal PK, Ghosn J, Giani M, Giaquinto C, Gibson J, Gigante T, Gilg M, Gilroy E, Giordano G, Girvan M, Gissot V, Gitahi J, Giwangkancana G, Glikman D, Glybochko P, Gnall E, Goco G, Goehringer F, Goepel S, Goffard JC, Goh JY, Golob J, Gomes R, Gomez K, Gómez-Junyent J, Gominet M, Gonzalez A, Gordon P, Gordon A, Gorenne I, Goubert L, Goujard C, Goulenok T, Grable M, Graf J, Grandin EW, Granier P, Grasselli G, Grazioli L, Green CA, Greene C, Greenhalf W, Greffe S, Grieco DL, Griffee M, Griffiths F, Grigoras I, Groenendijk A, Grosse Lordemann A, Gruner H, Gu Y, Guarracino F, Guedj J, Guego M, Guellec D, Guerguerian AM, Guerreiro D, Guery R, Guillaumot A, Guilleminault L, Guimarães de Castro M, Guimard T, Haalboom M, Haber D, Habraken H, Hachemi A, Hadri N, Haidash O, Haider S, Haidri F, Hakak S, Hall A, Hall M, Halpin S, Hamer A, Hamers R, Hamidfar R, Hammond T, Han LY, Haniffa R, Hao KW, Hardwick H, Harrison EM, Harrison J, Harrison SBE, Hartman A, Hashmi J, Hashmi M, Hayat M, Hayes A, Hays L, Heerman J, Heggelund L, Hendry R, Hennessy M, Henriquez A, Hentzien M, Herekar F, Hernandez-Montfort J, Herr D, Hershey A, Hesstvedt L, Hidayah A, Higgins D, Higgins E, HigginsOKeeffe G, Hinchion R, Hinton S, Hiraiwa H, Hitoto H, Ho A, Ho YB, Hoctin A, Hoffmann I, Hoh WH, Hoiting O, Holt R, Holter JC, Horby P, Horcajada JP, Hoshino K, Hoshino K, Houas I, Hough CL, Houltham S, Hsu JMY, Hulot JS, Hussain I, Ijaz S, Illes HG, Imbert P, Imran M, Imran Sikander R, Inácio H, Infante Dominguez C, Ing YS, Iosifidis E, Ippolito M, Isgett S, Ishani PGPI, Isidoro T, Ismail N, Isnard M, Itai J, Ito A, Ivulich D, Jaafar D, Jaafoura S, Jabot J, Jackson C, Jamieson N, Jaquet P, Jassat W, Jaud-Fischer C, Jaureguiberry S, Javidfar J, Jawad I, Jaworsky D, Jayakumar D, Jego F, Jelani AM, Jenum S, Jimbo-Sotomayor R, Job VDP, Joe OY, Jorge García RN, Joseph C, Joseph M, Joshi S, Jourdain M, Jouvet P, June J, Jung A, Jung H, Juzar D, Kafif O, Kaguelidou F, Kaisbain N, Kaleesvran T, Kali S, Kalicinska A, Kalomoiri S, Kamal S, Kamaluddin MAA, Kamaruddin ZAC, Kamarudin N, Kandamby DH, Kandel C, Kang KY, Kant R, Kanwal D, Kanyawati D, Karki B, Karpayah P, Karsies T, Kartsonaki C, Kasugai D, Kataria A, Katz K, Kaur A, Kaur Johal S, Kawasaki T, Kay C, Keane H, Keating S, Kellam P, Kelly A, Kelly A, Kelly C, Kelly N, Kelly S, Kelly Y, Kelsey M, Kennedy R, Kennon K, Kernan M, Kerroumi Y, Keshav S, Kestelyn E, Khalid I, Khalid O, Khalil A, Khan C, Khan I, Khanal S, Kho ME, Khoo D, Khoo R, Khoo S, Khoso N, Kiat KH, Kida Y, Kiiza P, Kildal AB, Kim JB, Kimmoun A, Kindgen-Milles D, King A, Kitamura N, Klenerman P, Klont R, Kloumann Bekken G, Knight S, Kobbe R, Kodippily C, Kohns Vasconcelos M, Koirala S, Komatsu M, Korten V, Kosgei C, Kpangon A, Krawczyk K, Krishnan S, Krishnan V, Kruglova O, Kumar A, Kumar D, Kumar G, Kumar M, Kumar Vecham P, Kuriakose D, Kurtzman E, Kusumastuti NP, Kutsogiannis D, Kutsyna G, Kyriakoulis K, Lachatre M, Lacoste M, Laffey JG, Lagrange M, Laine F, Lairez O, Lakhey S, Lalueza A, Lambert M, Lamontagne F, Langelot-Richard M, Langlois V, Lantang EY, Lanza M, Laouénan C, Laribi S, Lariviere D, Lasry S, Latif N, Launay O, Laureillard D, Lavie-Badie Y, Law A, Lawrence C, Lawrence T, Le M, Le Bihan C, Le Bris C, Le Falher G, Le Fevre L, Le Hingrat Q, Le Maréchal M, Le Mestre S, Le Moal G, Le Moing V, Le Nagard H, Le Turnier P, Leal E, Leal Santos M, Lee BH, Lee HG, Lee J, Lee SH, Lee TC, Lee YL, Leeming G, Lefebvre B, Lefebvre L, Lefevre B, LeGac S, Lelievre JD, Lellouche F, Lemaignen A, Lemee V, Lemeur A, Lemmink G, Lene HS, Lennon J, León R, Leone M, Leone M, Lepiller Q, Lescure FX, Lesens O, Lesouhaitier M, Lester-Grant A, Levy B, Levy Y, Levy-Marchal C, Lewandowska K, L'Her E, Li Bassi G, Liang J, Liaquat A, Liegeon G, Lim KC, Lim WS, Lima C, Lina B, Lina L, Lind A, Lingas G, Lion-Daolio S, Lissauer S, Liu K, Livrozet M, Lizotte P, Loforte A, Lolong N, Loon LC, Lopes D, Lopez-Colon D, Loschner AL, Loubet P, Loufti B, Louis G, Lourenco S, Lovelace-Macon L, Low LL, Lowik M, Loy JS, Lucet JC, Lumbreras Bermejo C, Luna CM, Lungu O, Luong L, Luque N, Luton D, Lwin N, Lyons R, Maasikas O, Mabiala O, MacDonald S, MacDonald S, Machado M, Macheda G, Macias Sanchez J, Madhok J, Maestro de la Calle G, Mahieu R, Mahy S, Maia AR, Maier LS, Maillet M, Maitre T, Malfertheiner M, Malik N, Mallon P, Maltez F, Malvy D, Manda V, Mandei JM, Mandelbrot L, Manetta F, Mangal K, Mankikian J, Manning E, Manuel A, Maria Sant`Ana Malaque C, Marino D, Marino F, Markowicz S, Maroun Eid C, Marques A, Marquis C, Marsh B, Marsh L, Marshal M, Marshall J, Martelli CT, Martin DA, Martin E, Martin-Blondel G, Martinelli A, Martin-Loeches I, Martinot M, Martin-Quiros A, Martins A, Martins J, Martins N, Martins Rego C, Martucci G, Martynenko O, Marwali EM, Marzukie M, Masa Jimenez JF, Maslove D, Maslove D, Mason P, Mason S, Masood S, Masood S, Mat Nor B, Matan M, Mateus Fernandes H, Mathew M, Mathieu D, Mattei M, Matulevics R, Maulin L, Maxwell M, Maynar J, Mazzoni T, Mc Sweeney L, McAndrew L, McArthur C, McCarthy A, McCarthy A, McCloskey C, McConnochie R, McDermott S, McDonald SE, McElroy A, McElwee S, McEneany V, McEvoy N, McGeer A, McKay C, McKeown J, McLean KA, McNally P, McNicholas B, McPartlan E, Meaney E, Mear-Passard C, Mechlin M, Meher M, Mehkri O, Mele F, Melo L, Memon K, Mendes JJ, Menkiti O, Menon K, Mentré F, Mentzer AJ, Mercier E, Mercier N, Merckx A, Mergeay-Fabre M, Mergler B, Merson L, Mesquita A, Metwally O, Meybeck A, Meyer D, Meynert AM, Meysonnier V, Meziane A, Mezidi M, Michelagnoli G, Michelanglei C, Michelet I, Mihelis E, Mihnovit V, Miranda-Maldonado H, Misnan NA, Mohamed NNE, Mohamed TJ, Moin A, Molina D, Molinos E, Molloy B, Mone M, Monteiro A, Montes C, Montrucchio G, Moore S, Moore SC, Morales Cely L, Moro L, Morocho Tutillo DR, Morton B, Motherway C, Motos A, Mouquet H, Mouton Perrot C, Moyet J, Mudara C, Mufti AK, Muh NY, Muhamad D, Mullaert J, Muller F, Müller KE, Munblit D, Muneeb S, Munir N, Munshi L, Murphy A, Murphy A, Murphy L, Murris M, Murthy S, Musaab H, Muyandy G, Myrodia DM, N N, Nagpal D, Nagrebetsky A, Narasimhan M, Narayanan N, Nasim Khan R, Nazerali-Maitland A, Neant N, Neb H, Nekliudov NA, Nelwan E, Neto R, Neumann E, Neves B, Ng PY, Nghi A, Nguyen D, Ni Choileain O, Ni Leathlobhair N, Nichol A, Nitayavardhana P, Nonas S, Noordin NAM, Noret M, Norharizam NFI, Norman L, Notari A, Noursadeghi M, Nowicka K, Nowinski A, Nseir S, Nunez JI, Nurnaningsih N, Nyamankolly E, O Brien F, O'Callaghan A, Occhipinti G, OConnor D, O'Donnell M, Ogston T, Ogura T, Oh TH, O'Halloran S, O'Hearn K, Ohshimo S, Oldakowska A, Oliveira J, Oliveira L, Olliaro PL, O'Neil C, Ong DS, Ong JY, Oosthuyzen W, Opavsky A, Openshaw P, Orakzai S, Orozco-Chamorro CM, Orquera A, Ortoleva J, Osatnik J, O'Shea L, O'Sullivan M, Othman SZ, Ouamara N, Ouissa R, Owyang C, Oziol E, Pabasara HMU, Pagadoy M, Pages J, Palacios A, Palacios M, Palmarini M, Panarello G, Panda PK, Paneru H, Pang LH, Panigada M, Pansu N, Papadopoulos A, Parke R, Parker M, Parra B, Parrini V, Pasha T, Pasquier J, Pastene B, Patauner F, Patel J, Pathmanathan MD, Patrão L, Patricio P, Patrier J, Patterson L, Pattnaik R, Paul C, Paul M, Paulos J, Paxton WA, Payen JF, Peariasamy K, Pedrera Jiménez M, Peek GJ, Peelman F, Peiffer-Smadja N, Peigne V, Pejkovska M, Pelosi P, Peltan ID, Pereira R, Perez D, Periel L, Perpoint T, Pesenti A, Pestre V, Petrou L, Petrov-Sanchez V, Pettersen FO, Peytavin G, Pharand S, Piagnerelli M, Picard W, Picone O, Piero MD, Pierobon C, Piersma D, Pimentel C, Pinto R, Pires C, Pironneau I, Piroth L, Pius R, Piva S, Plantier L, Plotkin D, Png HS, Poissy J, Pokeerbux R, Pokorska-Spiewak M, Poli S, Pollakis G, Ponscarme D, Popielska J, Post AM, Postma DF, Povoa P, Póvoas D, Powis J, Prapa S, Preau S, Prebensen C, Preiser JC, Prinssen A, Pritchard MG, Priyadarshani GDD, Proença L, Pudota S, Puéchal O, Pujo Semedi B, Pulicken M, Puntoni M, Purcell G, Quesada L, Quinones-Cardona V, Quirós González V, Quist-Paulsen E, Quraishi M, Rabaa M, Rabaud C, Rabindrarajan E, Rafael A, Rafiq M, Ragazzo G, Rahman AKHA, Rahman RA, Rahutullah A, Rainieri F, Rajahram GS, Rajapakse N, Ralib A, Ramakrishnan N, Ramanathan K, Ramli AA, Rammaert B, Ramos GV, Rana A, Rangappa R, Ranjan R, Rapp C, Rashan A, Rashan T, Rasheed G, Rasmin M, Rätsep I, Rau C, Ravi T, Raza A, Real A, Rebaudet S, Redl S, Reeve B, Rehan A, Rehman A, Reid L, Reid L, Reikvam DH, Reis R, Rello J, Remppis J, Remy M, Ren H, Renk H, Resende L, Resseguier AS, Revest M, Rewa O, Reyes LF, Reyes T, Ribeiro MI, Richardson D, Richardson D, Richier L, Ridzuan SNAA, Riera J, Rios AL, Rishu A, Rispal P, Risso K, Rivera Nuñez MA, Rizer N, Robb D, Robba C, Roberto A, Roberts S, Robertson DL, Robineau O, Roche-Campo F, Rodari P, Rodeia S, Rodriguez Abreu J, Roessler B, Roger C, Roger PM, Roilides E, Rojek A, Romaru J, Roncon-Albuquerque Jr R, Roriz M, Rosa-Calatrava M, Rose M, Rosenberger D, Rossanese A, Rossetti M, Rossignol B, Rossignol P, Rousset S, Roy C, Roze B, Rusmawatiningtyas D, Russell CD, Ryan M, Ryan M, Ryckaert S, Rygh Holten A, Saba I, Sadaf S, Sadat M, Sahraei V, Saint-Gilles M, Sakiyalak P, Salahuddin N, Salazar L, Saleem J, Saleem J, Sales G, Sallaberry S, Salmon Gandonniere C, Salvator H, Sanchez O, Sánchez Choez X, Sanchez de Oliveira K, Sanchez-Miralles A, Sancho-Shimizu V, Sandhu G, Sandhu Z, Sandrine PF, Sandulescu O, Santos M, Sarfo-Mensah S, Sarmento Banheiro B, Sarmiento ICE, Sarton B, Satyapriya S, Satyawati R, Saviciute E, Savio R, Savvidou P, Saw YT, Schaffer J, Schermer T, Scherpereel A, Schneider M, Schroll S, Schwameis M, Schwartz G, Scott JT, Scott-Brown J, Sedillot N, Seitz T, Selvanayagam J, Selvarajoo M, Semaille C, Semple MG, Senian RB, Senneville E, Sepulveda C, Sequeira F, Sequeira T, Serpa Neto A, Serrano Balazote P, Shadowitz E, Shahidan SA, Shahnaz Hasan M, Shamsah M, Shankar A, Sharjeel S, Sharma P, Shaw CA, Shaw V, Shi H, Shiban N, Shiekh M, Shiga T, Shime N, Shimizu H, Shimizu K, Shimizu N, Shindo N, Shrapnel S, Shum HP, Si Mohammed N, Siang NY, Sibiude J, Siddiqui A, Sigfrid L, Sillaots P, Silva C, Silva MJ, Silva R, Sim Lim Heng B, Sin WC, Singh BC, Singh P, Sitompul PA, Sivam K, Skogen V, Smith S, Smood B, Smyth C, Smyth M, Smyth M, Snacken M, So D, Soh TV, Solis M, Solomon J, Solomon T, Somers E, Sommet A, Song MJ, Song R, Song T, Song Chia J, Sonntagbauer M, Soom AM, Sotto A, Soum E, Sousa AC, Sousa M, Sousa Uva M, Souza-Dantas V, Sperry A, Spinuzza E, Sri Darshana BPSR, Sriskandan S, Stabler S, Staudinger T, Stecher SS, Steinsvik T, Stienstra Y, Stiksrud B, Stolz E, Stone A, Streinu-Cercel A, Streinu-Cercel A, Strudwick S, Stuart A, Stuart D, Subekti D, Suen G, Suen JY, Sukumar P, Sultana A, Summers C, Supic D, Suppiah D, Surovcová M, Suwarti S, Svistunov AA, Syahrin S, Syrigos K, Sztajnbok J, Szuldrzynski K, Tabrizi S, Taccone FS, Tagherset L, Taib SM, Talarek E, Taleb S, Talsma J, Tampubolon ML, Tan KK, Tan LV, Tan YC, Tanaka C, Tanaka H, Tanaka T, Taniguchi H, Tanveer H, Taqdees H, Taqi A, Tardivon C, Tattevin P, Taufik MA, Tawfik H, Tedder RS, Tee TY, Teixeira J, Tejada S, Tellier MC, Teoh SK, Teotonio V, Téoulé F, Terpstra P, Terrier O, Terzi N, Tessier-Grenier H, Tey A, Thabit AAM, Tham ZD, Thangavelu S, Thibault V, Thiberville SD, Thill B, Thirumanickam J, Thompson S, Thomson D, Thomson EC, Thurai SRT, Thuy DB, Thwaites RS, Tierney P, Tieroshyn V, Timashev PS, Timsit JF, Tirupakuzhi Vijayaraghavan BK, Tissot N, Toh JZY, Toki M, Tolppa T, Tonby K, Tonnii SL, Torres A, Torres M, Torres Santos-Olmo RM, Torres-Zevallos H, Towers M, Trapani T, Traynor D, Treoux T, Trieu HT, Tripathy S, Tromeur C, Trontzas I, Trouillon T, Truong J, Tual C, Tubiana S, Tuite H, Turmel JM, Turtle LC, Tveita A, Twardowski P, Uchiyama M, Udayanga PGI, Udy A, Ullrich R, Umer Z, Uribe A, Usman A, Vajdovics C, Val-Flores L, Valle AL, Valran A, Van de Velde S, van den Berge M, van der Feltz M, van der Valk P, Van Der Vekens N, Van der Voort P, Van Der Werf S, van Dyk M, van Gulik L, Van Hattem J, van Lelyveld S, van Netten C, Van Twillert G, van Veen I, Vanel N, Vanoverschelde H, Varghese P, Varrone M, Vasudayan SR, Vauchy C, Vaughan H, Veeran S, Veislinger A, Vencken S, Ventura S, Verbon A, Vidal JE, Vieira C, Vijayan D, Villanueva JA, Villar J, Villeneuve PM, Villoldo A, Vinh Chau NV, Visseaux B, Visser H, Vitiello C, Vonkeman H, Vuotto F, Wahab NH, Wahab SA, Wahid NA, Wainstein M, Wan Muhd Shukeri WF, Wang CH, Webb SA, Wei J, Weil K, Wen TP, Wesselius S, West TE, Wham M, Whelan B, White N, Wicky PH, Wiedemann A, Wijaya SO, Wille K, Willems S, Williams V, Wils EJ, Wing Yiu N, Wong C, Wong TF, Wong XC, Wong YS, Xian GE, Xian LS, Xuan KP, Xynogalas I, Yacoub S, Yakop SRBM, Yamazaki M, Yazdanpanah Y, Yee Liang Hing N, Yelnik C, Yeoh CH, Yerkovich S, Yokoyama T, Yonis H, Yousif O, Yuliarto S, Zaaqoq A, Zabbe M, Zacharowski K, Zahid M, Zahran M, Zaidan NZB, Zambon M, Zambrano M, Zanella A, Zawadka K, Zaynah N, Zayyad H, Zoufaly A, Zucman D. The value of open-source clinical science in pandemic response: lessons from ISARIC. Lancet Infect Dis 2021; 21:1623-1624. [PMID: 34619109 PMCID: PMC8489876 DOI: 10.1016/s1473-3099(21)00565-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/09/2021] [Accepted: 08/16/2021] [Indexed: 12/31/2022]
|
18
|
Diallo MSK, Ayouba A, Keita AK, Thaurignac G, Sow MS, Kpamou C, Barry TA, Msellati P, Etard JF, Peeters M, Ecochard R, Delaporte E, Toure A, Ayouba A, Baize S, Bangoura K, Barry A, Barry M, Cissé M, Cissé M, Delaporte E, Delfraissy JF, Delmas C, Desclaux A, Diallo SB, Diallo MS, Diallo MS, Étard JF, Etienne C, Faye O, Fofana I, Granouillac B, Izard S, Kassé D, Keita AK, Keita S, Koivogui L, Kpamou C, Lacarabaratz C, Leroy S, Marchal CL, Levy Y, Magassouba N, March L, Mendiboure V, Msellati P, Niane H, Peeters M, Pers YM, Raoul H, Sacko SL, Savané I, Sow MS, Taverne B, Touré A, Traoré FA, Traoré F, Youla Y, Yazdanpanah Y. Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study. The Lancet Microbe 2021; 2:e676-e684. [DOI: 10.1016/s2666-5247(21)00170-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Revised: 06/16/2021] [Accepted: 06/16/2021] [Indexed: 12/19/2022] Open
|
19
|
Perreau M, Suffiotti M, Marques-Vidal P, Wiedemann A, Levy Y, Laouénan C, Ghosn J, Fenwick C, Comte D, Roger T, Regina J, Vollenweider P, Waeber G, Oddo M, Calandra T, Pantaleo G. The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nat Commun 2021; 12:4888. [PMID: 34373466 PMCID: PMC8352963 DOI: 10.1038/s41467-021-25191-5] [Citation(s) in RCA: 55] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Accepted: 07/15/2021] [Indexed: 12/12/2022] Open
Abstract
The objective of the present study was to identify biological signatures of severe coronavirus disease 2019 (COVID-19) predictive of admission in the intensive care unit (ICU). Over 170 immunological markers were investigated in a 'discovery' cohort (n = 98 patients) of the Lausanne University Hospital (LUH-1). Here we report that 13 out of 49 cytokines were significantly associated with ICU admission in the three cohorts (P < 0.05 to P < 0.001), while cellular immunological markers lacked power in discriminating between ICU and non-ICU patients. The cytokine results were confirmed in two 'validation' cohorts, i.e. the French COVID-19 Study (FCS; n = 62) and a second LUH-2 cohort (n = 47). The combination of hepatocyte growth factor (HGF) and C-X-C motif chemokine ligand 13 (CXCL13) was the best predictor of ICU admission (positive and negative predictive values ranging from 81.8% to 93.1% and 85.2% to 94.4% in the 3 cohorts) and occurrence of death during patient follow-up (8.8 fold higher likelihood of death when both cytokines were increased). Of note, HGF is a pleiotropic cytokine with anti-inflammatory properties playing a fundamental role in lung tissue repair, and CXCL13, a pro-inflammatory chemokine associated with pulmonary fibrosis and regulating the maturation of B cell response. Up-regulation of HGF reflects the most powerful counter-regulatory mechanism of the host immune response to antagonize the pro-inflammatory cytokines including CXCL13 and to prevent lung fibrosis in COVID-19 patients.
Collapse
Affiliation(s)
- Matthieu Perreau
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Madeleine Suffiotti
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Pedro Marques-Vidal
- Service of Internal Medicine, Department of Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Aurelie Wiedemann
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France.,Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique, Créteil, France
| | - Yves Levy
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France.,Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique, Créteil, France
| | - Cédric Laouénan
- AP-HP, Hôpital Bichat, Département Épidémiologie Biostatistiques et Recherche Clinique, INSERM, Centre d'Investigation clinique-Epidémiologie Clinique 1425, Paris, France.,Université de Paris, INSERM, IAME UMR 1137, Paris, France
| | - Jade Ghosn
- AP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, Paris, France
| | - Craig Fenwick
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Denis Comte
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Thierry Roger
- Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Jean Regina
- Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Peter Vollenweider
- Service of Internal Medicine, Department of Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Gerard Waeber
- Service of Internal Medicine, Department of Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Mauro Oddo
- Service of Intensive Care, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Thierry Calandra
- Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Giuseppe Pantaleo
- Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. .,Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France. .,Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
| |
Collapse
|
20
|
Spiera R, Kuwana M, Khanna D, Hummers L, Frech T, Stevens W, Gordon J, Kafaja S, Matucci-Cerinic M, Distler O, Lee EB, Levy Y, Jun JB, Constantine S, Dgetluck N, White B, Furst D, Denton C. OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC). Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1795] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Lenabasum is an oral CB2 agonist that attenuates inflammation and fibrosis in SSc animal models and showed clinical benefit with acceptable safety in a Phase 2 trial in dcSSc.Objectives:Test efficacy and safety of lenabasum in a Phase 3 trial in dcSSc.Methods:Subjects ≥18 years old with disease duration ≤ 6 years were randomized 1:1:1 to lenabasum 5 mg, 20 mg, or placebo (PBO), all BID, with stable background immunosuppressant therapy (IST) allowed. The primary efficacy endpoint was ACR CRISS score, and secondary endpoints were ΔmRSS, ΔHAQ-DI, and ΔFVC, all at Week 52 for lenabasum 20 mg vs PBO.Results:363 adults were dosed; 37 (10%) stopped study drug early, with only 1 subject (PBO cohort) stopping due to adverse event (AE). Baseline demographics were similar among groups. Disease duration was ≤ 3 years in 60% and 66%, mean mRSS score was 22.0 and 23.3, and background IST was used by 89% and 84% of lenabasum 20 mg and PBO groups, respectively.Safety results showed serious AEs and severe AEs occurred in 9.2% and 5.8% vs 14.6% and 13.0%, respectively, of lenabasum 20 mg and PBO groups.Efficacy results (Table) demonstrated:Table 1.Primary and secondary efficacy endpoints and post-hoc analyses, Week 52Group, by IST treatmentCohortNΔmRSS, mean (SD)ΔFVC% mean (SD)ΔFVC, mL mean (SD)ΔHAQ-DI mean (SD)ACR CRISS medianmITT population, MMRM primary analysis methodAllPlacebo123-8.1 (7.72)-1.0 (8.68)-51 (317)-0.13 (0.468)0.887Lenabasum 20 mg120-6.7 (6.59)-1.6 (6.91)-78 (265)-0.13 (0.436)0.888Placebo subjects, per protocol completers, LOCFNo ISTPlacebo16-2.3 (9.4)-2.8 (7.4)-97 (244)0.12 (0.34)0.417All ISTPlacebo97-8.9 (7.07)-1.0 (9.2)-43 (330)-0.17 (0.474)0.936MMF, no other ISTPlacebo29-10.7 (8.1)-0.58 (7.1)-37 (235)-0.12 (0.456)0.935MMF ≤ 2 years, no other ISTPlacebo23-11.7 (8.1)-0.3 (6.0)-41 (197)-0.13 (0.495)0.935Non-MMF ≤ 2 yearsPlacebo24-6.7 (6.2)-1.4 (7.87)-52 (281)-0.15 (0.357)0.931Post-hoc comparisons, per protocol completers, LOCFNo ISTPlacebo16-2.3 (9.4)-2.8 (7.4)-97 (244)0.12 (0.34)0.417Lenabasum 20 mg10-6.3 (6.02)-2.3 (5.58)-99 (209)-0.06 (0.498)0.811Established IST1Placebo26-6.1 (5.35)-4.6 (10.11)-170 (350)-0.17 (0.445)0.619Lenabasum 20 mg38-7.4 (5.08)-0.4 (5.70)2-21 (233)3-0.07 (0.357)0.941Established IST, subjects with ILDPlacebo22-5.9 (5.28)-3.7 (5.43)-133 (206)-0.10 (0.372)0.553Lenabasum 20 mg33-7.2 (5.70)-1.0 (10.5)-47 (365)-0.06 (0.391)0.8192 P = 0.0386 two-sample t-test; 3 P = 0.0481 two-sample t-test; other comparisons were not significant• No significant differences were seen in primary and secondary efficacy endpoints. Primary MMRM analyses with treatment-by-time-by-subgroup interactions showed that background mycophenolate (MMF) significantly influenced the outcome•oSubjects on no IST with disease duration ≤3 years were only 7% of PBO subjects and showed little improvement on PBO, in line with other dcSSc trials in which IST was restricted. Post-hoc subgroup analyses of these subjects on no IST suggested improvement in ΔmRSS and ΔHAQ-DI, for lenabasum 20 mg vs PBO•uUnexpectedly high improvement occurred in PBO subjects receiving IST, notably those on MMF started within 2 years of baseline•nPost-hoc analyses of subjects on established IST (MMF or, if no MMF, ≥ 1 non-MMF IST started > 2 years before baseline) suggested improvement in ΔFVC% (nominal P = 0.0386) and ΔFVC mL (nominal P = 0.0481) for lenabasum 20 mg vs PBO. Improvement in FVC was also seen in subjects on established IST who had ILD at baseline, lenabasum 20 mg vs PBO•mACR CRISS score demonstrated a ceiling effect and correlated most highly with ΔmRSS (r = -0.739) and moderately with MDGA (-0.432), HAQ-DI (-0.362), FVC% (0.366), and PtGA (-0.288)Conclusion:Lenabasum was safely used in this study. Unexpectedly high improvement on background IST, especially MMF, has not been previously reported at this level. The primary endpoint was not met. Post-hoc analyses showed greater improvement in lenabasum- vs PBO-treated subjects who were not on background IST and those on established IST, including subjects with ILD.Disclosure of Interests:Robert Spiera Consultant of: Abbvie, Roche-Genetech, GSK, CSL Behring, Sanofi, Janssen, Chemocentryx, Formation Biologics, Mitsubishi Tanabe, Grant/research support from: Roche-Genetech, GSK, Boehringer Ingelheim, Chemocentryx, Corbus, Formation Biologics, Sanofi, Inflarx, Astra Zeneca, Kadmon, Masataka Kuwana Speakers bureau: Boehringer-Ingelheim, Chugai, Janssen, Consultant of: Boehringer-Ingelheim, Chugai, Corbus, Grant/research support from: Boehringer-Ingelheim, Chugai, MBL, Ono Pharmaceuticals, Tanabe-Mitsubishi, Dinesh Khanna Shareholder of: Eicos Sciences, Inc (less than 5%). Leadership/Equity position – Chief Medical Officer, CiviBioPharma/Eicos Sciences, Inc, Consultant of: Acceleron, Actelion, Abbvie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Gilead, Galapagos, Genentech/Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics, Grant/research support from: NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer, Laura Hummers Consultant of: CSL Behring, Boehringer Ingelheim, Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals. Corbus, Boehringer Ingelheim, Medpace, Kadmon, Cumberland, CSL Behring, Tracy Frech Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals, Wendy Stevens Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals, Jessica Gordon Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals. Research funding for EICOS Pharmaceuticals and Cumberland Pharmaceuticals., Suzanne Kafaja Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals, Marco Matucci-Cerinic Consultant of: Actelion, Janssen, Inventiva, Bayer, Biogen, Boehringer, CSL Behring, Corbus, Galapagos, Mitsubishi, Samsung, Regeneron, Acceleron, MSD, Chemomab, Lilly, Pfizer, Roche, Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals, Oliver Distler Consultant of: Consultancy relationship and/or has received research funding in the area of potential treatments for systemic sclerosis and its complications from (last three years): Abbvie, Acceleron Pharma, Amgen, AnaMar, Arxx Therapeutics, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, ChemomAb, Corbus Pharmaceuticals, CSL Behring, Galapagos NV, Glenmark Pharmaceuticals, GSK, Horizon (Curzion) Pharmaceuticals, Inventiva, iQvia, Italfarmaco, iQone, Kymera Therapeutics, Lilly, Medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Serodapharm, Topadur, Target Bioscience and UCB., Eun Bong Lee Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals, Yair Levy Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals, Jae-Bum Jun Consultant of: Consultant to Boehringer Ingelheim Korea, Jeil Pharma, Dae Woong Pharma, Kwangdong Pharma, and Sama Pharma., Grant/research support from: Investigator for study sponsored by Corbus Pharmaceuticals, Scott Constantine Employee of: Employee of Corbus Pharmaceuticals, Nancy Dgetluck Employee of: Employee of Corbus Pharmaceuticals, Barbara White Employee of: Employee and stockholder of Corbus Pharmaceuticals, Daniel Furst Consultant of: Corbus, Galapagos, Pfizer, CSL Behring, Mitsubishi Tanabi, Actelion, Amgen, Novartis, Roche/Genentech, Gilead, Talaris, and Boehringer Ingelheim., Grant/research support from: grants from Corbus, Galapagos, GSK, Pfizer, Talaris, CSL Behring, Mitsubishi Tanabi, Christopher Denton Consultant of: Consultancy fees and/or honoraria from Corbus, Actelion, GlaxoSmithKline, Bayer, Sanofi, Galapagos, Inventiva, Boehringer Ingelheim, Roche, CSL Behring, Acceleron, Horizon, Arxx Therapeutics
Collapse
|
21
|
Cheng L, Li G, Pellegry CM, Yasui F, Li F, Zurawski SM, Zurawski G, Levy Y, Ting JPY, Su L. TLR9- and CD40-Targeting Vaccination Promotes Human B Cell Maturation and IgG Induction via pDC-Dependent Mechanisms in Humanized Mice. Front Immunol 2021; 12:672143. [PMID: 34093572 PMCID: PMC8169971 DOI: 10.3389/fimmu.2021.672143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Accepted: 04/27/2021] [Indexed: 12/15/2022] Open
Abstract
Mice reconstituted with a human immune system (humanized mice) provide a robust model to study human immunology, vaccinology, and human infectious diseases. However, the development and function of B cells in humanized mice is impaired. B cells from humanized mice are immature and are impaired in IgM to IgG isotype switch in response to infection or vaccination. In the present study we report that Toll-like receptor 9 (TLR9) agonist CpG-B combined with CD40-targeting vaccination triggered human B cell immunoglobin class-switch from IgM+ to IgG+ B cells in humanized mice. Human B cells from mice vaccinated with CpG-B as adjuvant were more mature in phenotype and produced significant levels of both total IgG and antigen-specific IgG. We found that CpG-B treatment activated human pDCs (plasmacytoid dendritic cells) in vivo to induce interferon-alpha (IFN-α)expression in humanized mice. Pre-depletion of human pDC in vivo abrogated the adjuvant effect of CpG-B. Our results indicate that TLR9 and CD40-targeting vaccination triggers human B cell maturation and immunoglobulin class-switch in a pDC-dependent manner in humanized mice. The findings also shed light on induction of human IgG antibodies in humanized mouse models.
Collapse
Affiliation(s)
- Liang Cheng
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.,Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Wuhan University, Wuhan, China
| | - Guangming Li
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.,Division of Virology, Pathogenesis and Cancer, Institute of Human Virology, Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, United States
| | - Caroline Marnata Pellegry
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Fumihiko Yasui
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.,Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Feng Li
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.,Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Sandra M Zurawski
- Baylor Institute for Immunology Research, Vaccine Research Institute, INSERM U955, Dallas, TX, United States
| | - Gerard Zurawski
- Baylor Institute for Immunology Research, Vaccine Research Institute, INSERM U955, Dallas, TX, United States
| | - Yves Levy
- Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France.,Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Créteil, France
| | - Jenny P-Y Ting
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.,Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.,Department of Microbiology-Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
| | - Lishan Su
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.,Division of Virology, Pathogenesis and Cancer, Institute of Human Virology, Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD, United States
| |
Collapse
|
22
|
Rosenbaum P, Tchitchek N, Joly C, Rodriguez Pozo A, Stimmer L, Langlois S, Hocini H, Gosse L, Pejoski D, Cosma A, Beignon AS, Dereuddre-Bosquet N, Levy Y, Le Grand R, Martinon F. Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response. Front Immunol 2021; 12:645210. [PMID: 33959127 PMCID: PMC8093451 DOI: 10.3389/fimmu.2021.645210] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 04/06/2021] [Indexed: 01/12/2023] Open
Abstract
Vaccination is one of the most efficient public healthcare measures to fight infectious diseases. Nevertheless, the immune mechanisms induced in vivo by vaccination are still unclear. The route of administration, an important vaccination parameter, can substantially modify the quality of the response. How the route of administration affects the generation and profile of immune responses is of major interest. Here, we aimed to extensively characterize the profiles of the innate and adaptive response to vaccination induced after intradermal, subcutaneous, or intramuscular administration with a modified vaccinia virus Ankara model vaccine in non-human primates. The adaptive response following subcutaneous immunization was clearly different from that following intradermal or intramuscular immunization. The subcutaneous route induced a higher level of neutralizing antibodies than the intradermal and intramuscular vaccination routes. In contrast, polyfunctional CD8+ T-cell responses were preferentially induced after intradermal or intramuscular injection. We observed the same dichotomy when analyzing the early molecular and cellular immune events, highlighting the recruitment of cell populations, such as CD8+ T lymphocytes and myeloid-derived suppressive cells, and the activation of key immunomodulatory gene pathways. These results demonstrate that the quality of the vaccine response induced by an attenuated vaccine is shaped by early and subtle modifications of the innate immune response. In this immunization context, the route of administration must be tailored to the desired type of protective immune response. This will be achieved through systems vaccinology and mathematical modeling, which will be critical for predicting the efficacy of the vaccination route for personalized medicine.
Collapse
Affiliation(s)
- Pierre Rosenbaum
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Nicolas Tchitchek
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Candie Joly
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - André Rodriguez Pozo
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Lev Stimmer
- INSERM, U1169, Kremlin-Bicêtre, France
- CEA – INSERM, MIRCen, UMS27, Fontenay-aux-Roses, France
| | - Sébastien Langlois
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Hakim Hocini
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
- INSERM, U955, Team 16, Clinical and Infectious Diseases Department, Hospital Henri Mondor, University of Paris East, Créteil, France
| | - Leslie Gosse
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - David Pejoski
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Antonio Cosma
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Anne-Sophie Beignon
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Nathalie Dereuddre-Bosquet
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Yves Levy
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
- INSERM, U955, Team 16, Clinical and Infectious Diseases Department, Hospital Henri Mondor, University of Paris East, Créteil, France
| | - Roger Le Grand
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Frédéric Martinon
- UMR1184 IMVA-HB, IDMIT Department, Université Paris-Saclay – INSERM U1184 – CEA, Fontenay-aux-Roses, France
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| |
Collapse
|
23
|
Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, Leyssen M, Luhn K, Richert L, Bétard C, Gibani MM, Clutterbuck EA, Snape MD, Levy Y, Douoguih M, Thiebaut R. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2020; 21:493-506. [PMID: 33217361 DOI: 10.1016/s1473-3099(20)30476-x] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 04/09/2020] [Accepted: 05/06/2020] [Indexed: 01/24/2023]
Abstract
BACKGROUND To address the unmet medical need for an effective prophylactic vaccine against Ebola virus we assessed the safety and immunogenicity of three different two-dose heterologous vaccination regimens with a replication-deficient adenovirus type 26 vector-based vaccine (Ad26.ZEBOV), expressing Zaire Ebola virus glycoprotein, and a non-replicating, recombinant, modified vaccinia Ankara (MVA) vector-based vaccine, encoding glycoproteins from Zaire Ebola virus, Sudan virus, and Marburg virus, and nucleoprotein from the Tai Forest virus. METHODS This randomised, observer-blind, placebo-controlled, phase 2 trial was done at seven hospitals in France and two research centres in the UK. Healthy adults (aged 18-65 years) with no history of Ebola vaccination were enrolled into four cohorts. Participants in cohorts I-III were randomly assigned (1:1:1) using computer-generated randomisation codes into three parallel groups (randomisation for cohorts II and III was stratified by country and age), in which participants were to receive an intramuscular injection of Ad26.ZEBOV on day 1, followed by intramuscular injection of MVA-BN-Filo at either 28 days (28-day interval group), 56 days (56-day interval group), or 84 days (84-day interval group) after the first vaccine. Within these three groups, participants in cohort II (14:1) and cohort III (10:3) were further randomly assigned to receive either Ad26.ZEBOV or placebo on day 1, followed by either MVA-BN-Filo or placebo on days 28, 56, or 84. Participants in cohort IV were randomly assigned (5:1) to receive one dose of either Ad26.ZEBOV or placebo on day 1 for vector shedding assessments. For cohorts II and III, study site personnel, sponsor personnel, and participants were masked to vaccine allocation until all participants in these cohorts had completed the post-MVA-BN-Filo vaccination visit at 6 months or had discontinued the trial, whereas cohort I was open-label. For cohort IV, study site personnel and participants were masked to vaccine allocation until all participants in this cohort had completed the post-vaccination visit at 28 days or had discontinued the trial. The primary outcome, analysed in all participants who had received at least one dose of vaccine or placebo (full analysis set), was the safety and tolerability of the three vaccination regimens, as assessed by participant-reported solicited local and systemic adverse events within 7 days of receiving both vaccines, unsolicited adverse events within 42 days of receiving the MVA-BN-Filo vaccine, and serious adverse events over 365 days of follow-up. The secondary outcome was humoral immunogenicity, as measured by the concentration of Ebola virus glycoprotein-binding antibodies at 21 days after receiving the MVA-BN-Filo vaccine. The secondary outcome was assessed in the per-protocol analysis set. This study is registered at ClinicalTrials.gov, NCT02416453, and EudraCT, 2015-000596-27. FINDINGS Between June 23, 2015, and April 27, 2016, 423 participants were enrolled: 408 in cohorts I-III were randomly assigned to the 28-day interval group (123 to receive Ad26.ZEBOV and MVA-BN-Filo, and 13 to receive placebo), the 56-day interval group (124 to receive Ad26.ZEBOV and MVA-BN-Filo, and 13 to receive placebo), and the 84-day interval group (117 to receive Ad26.ZEBOV and MVA-BN-Filo, and 18 to receive placebo), and 15 participants in cohort IV were assigned to receive Ad26.ZEBOV and MVA-BN-Filo (n=13) or to receive placebo (n=2). 421 (99·5%) participants received at least one dose of vaccine or placebo. The trial was temporarily suspended after two serious neurological adverse events were reported, one of which was considered as possibly related to vaccination, and per-protocol vaccination was disrupted for some participants. Vaccinations were generally well tolerated. Mild or moderate local adverse events (mostly pain) were reported after 206 (62%) of 332 Ad26.ZEBOV vaccinations, 136 (58%) of 236 MVA-BN-Filo vaccinations, and 11 (15%) of 72 placebo injections. Systemic adverse events were reported after 255 (77%) Ad26.ZEBOV vaccinations, 116 (49%) MVA-BN-Filo vaccinations, and 33 (46%) placebo injections, and included mostly mild or moderate fatigue, headache, or myalgia. Unsolicited adverse events occurred after 115 (35%) of 332 Ad26.ZEBOV vaccinations, 81 (34%) of 236 MVA-BN-Filo vaccinations, and 24 (33%) of 72 placebo injections. At 21 days after receiving the MVA-BN-Filo vaccine, geometric mean concentrations of Ebola virus glycoprotein-binding antibodies were 4627 ELISA units (EU)/mL (95% CI 3649-5867) in the 28-day interval group, 10 131 EU/mL (8554-11 999) in the 56-day interval group, and 11 312 mL (9072-14106) in the 84-day interval group, with antibody concentrations persisting at 1149-1205 EU/mL up to day 365. INTERPRETATION The two-dose heterologous regimen with Ad26.ZEBOV and MVA-BN-Filo was safe, well tolerated, and immunogenic, with humoral and cellular immune responses persisting for 1 year after vaccination. Taken together, these data support the intended prophylactic indication for the vaccine regimen. FUNDING Innovative Medicines Initiative and Janssen Vaccines & Prevention BV. TRANSLATION For the French translation of the abstract see Supplementary Materials section.
Collapse
Affiliation(s)
- Andrew J Pollard
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford UK; NIHR Oxford Biomedical Research Centre, Oxford, UK
| | - Odile Launay
- Université de Paris, INSERM CIC 1417, F-CRIN I-REIVAC, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France
| | - Jean-Daniel Lelievre
- Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, INSERM U955, Créteil, France; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Créteil, France
| | - Christine Lacabaratz
- Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, INSERM U955, Créteil, France
| | - Sophie Grande
- Allergology and Clinical Immunology, LYREC, Lyon University Hospital, France
| | | | | | | | - Viki Bockstal
- Janssen Vaccines & Prevention BV, Leiden, Netherlands
| | - Aurelie Wiedemann
- Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, INSERM U955, Créteil, France
| | | | - Kerstin Luhn
- Janssen Vaccines & Prevention BV, Leiden, Netherlands
| | - Laura Richert
- University Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, INSERM, CHU Bordeaux, Bordeaux, France; CIC, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France; Inria SISTM team, F-33405, Talence, France
| | - Christine Bétard
- University Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, INSERM, CHU Bordeaux, Bordeaux, France; CIC, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France
| | - Malick M Gibani
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford UK; NIHR Oxford Biomedical Research Centre, Oxford, UK
| | - Elizabeth A Clutterbuck
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford UK; NIHR Oxford Biomedical Research Centre, Oxford, UK
| | - Matthew D Snape
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford UK; NIHR Oxford Biomedical Research Centre, Oxford, UK
| | - Yves Levy
- Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil, INSERM U955, Créteil, France
| | | | - Rodolphe Thiebaut
- University Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, INSERM, CHU Bordeaux, Bordeaux, France; CIC, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France; Inria SISTM team, F-33405, Talence, France.
| | | |
Collapse
|
24
|
Ceglia V, Zurawski S, Montes M, Bouteau A, Wang Z, Ellis J, Kroll M, Igyarto BZ, Levy Y, Zurawski G. Dendritic cell targeting anti-CD40 antibody-CD40L-HIV-1 vaccines are adjuvant intrinsic. The Journal of Immunology 2020. [DOI: 10.4049/jimmunol.204.supp.167.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Soluble CD40L and agonistic anti-CD40 monoclonal antibody are adjuvants used in vaccination settings. Vaccines based on anti-CD40 antibodies fused to HIV-1 antigens are in clinical development. Studies with current anti-CD40-based dendritic cell (DC) targeting vaccines show that co-administration of an adjuvant is needed for maximal immune responses. We show that by fusing CD40L to CD40-targeting antibodies, activation of DCs concomitant with antigen uptake and processing is maximized, and this provides a context CD40-targeting vaccines with intrinsic adjuvant activity. Direct fusion of CD40L to L or H chain C-termini results in CD40 agonists with ‘superagonist’ properties. Especially on DCs, both potency and efficacy for induction of cytokine secretion and activation markers is greatly enhanced compared to known strong agonists like Pfizer’s anti-CD40 CP-870-89 antibody. This potency was maintained by anti-CD40-CD40L constructs fused to HIV-1 antigens from Gag, Nef, and Pol regions (HIV5pep). Anti-CD40-CD40L-HIV5pep preferentially expanded CD8+ T cells from HIV-1+ donor PBMCs compared to the same antibody-antigen fusions without attached CD40L. Anti-CD40-CD40L-TEα and anti-CD40-TEα both evoked robust proliferation of TEα-specific CD4+ T cells in human CD40 transgenic mice, but only anti-CD40-CD40L-TEα vaccine elicited TEα-specific CD4+ T cells producing IFNγ. Also, anti-CD40-CD40L-Env gp140 vaccine without adjuvant in human CD40 transgenic mice elicited stronger anti-Env gp140 antibody responses than anti-CD40-Env gp140 vaccine. Thus superagonist anti-CD40 antibodies directly fused to the natural ligand show great advantage in inducing immune responses without the use of an extrinsic adjuvant.
Collapse
Affiliation(s)
- Valentina Ceglia
- 1Baylor Inst. for Immunology Res
- 2Facultè de Mèdicine, Universitè Paris Est-Crèteil, France
- 3Vaccine Research Institute (VRI), France
| | - Sandy Zurawski
- 1Baylor Inst. for Immunology Res
- 3Vaccine Research Institute (VRI), France
| | | | - Aurelie Bouteau
- 4Thomas Jefferson University
- 5Institute of Biomedical Studies, Baylor University
| | | | | | | | | | - Yves Levy
- 2Facultè de Mèdicine, Universitè Paris Est-Crèteil, France
- 3Vaccine Research Institute (VRI), France
| | - Gerard Zurawski
- 1Baylor Inst. for Immunology Res
- 3Vaccine Research Institute (VRI), France
| |
Collapse
|
25
|
Couffignal C, Kolta S, Flamant M, Cazanave C, Haymann JP, Mentré F, Duval X, Leport C, Raffi F, Chêne G, Salamon R, Moatti JP, Pierret J, Spire B, Brun-Vézinet F, Fleury H, Masquelier B, Peytavin G, Garraffo R, Costagliola D, Dellamonica P, Katlama C, Meyer L, Salmon D, Sobel A, Cuzin L, Dupon M, Le Moing V, Marchou B, May T, Morlat P, Rabaud C, Waldner-Combernoux A, Hardel L, Reboud P, Couffin-Cadiergues S, Marchand L, Assuied A, Carrieri P, Habak S, Couturier F, Jadand C, Perrier A, Préau M, Protopopescu C, Schmit J, Chennebault J, Faller J, Magy-Bertrand N, Chirouze C, Humbert P, Longy-Boursier, Neau D, Granier P, Ansart S, Verdon R, Merrien D, Chevojon P, Sobel A, Levy Y, Piroth L, Perronne C, Froguel E, Ceccaldi J, Chidiac C, Grégoire V, Reynes J, Fuzibet JG, Arsac P, Bouvet E, Bricaire F, Monsonego J, Girard P, Guillevin L, Herson S, Molina J, Pialoux G, Sain O, Sellier P, Roblot F, Bani-Sadr F, Michelet C, Lucht F, Debord C, Martin T, De Jaureguiberry J, Bernard L. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy. AIDS Res Hum Retroviruses 2020; 36:399-405. [PMID: 31891665 DOI: 10.1089/aid.2019.0229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
We assessed bone mineral density (BMD) in a cohort of human immunodeficiency virus (HIV)-positive patients after a median of 11 years of combination antiretroviral therapy (cART) and evaluated the respective role of HIV infection and antiretroviral drugs (ARVs). A cross-sectional study of 162 participants (131 male) from the ANRS-C08 cohort was performed with bone dual-energy X-ray absorptiometry (DXA) scans and renal assessment. The window of exposure to ARVs was defined as an exposure of more than six cumulative months during the last 3 years before the DXA evaluation to account for a cumulative exposure that could affect bone remodeling. The association with low BMD (Z-score < -2) was assessed by a multiple logistic regression model. The study population was 50 years (median), hepatitis C virus (HCV) (18%), and hepatitis B virus (HBV) (8%) coinfection with HIV-RNA <50 c/mL in 89%, median CD4 of 619/mm3. Prevalence of low BMD was 18% in males and 6% in females. The factors associated with a Z-score < -2 in males were uric acid renal loss [adjusted odds ratio (aOR): 6.1; 95% confidence interval (CI): 1.2-31.5; p = .03], HCV coinfection (aOR: 4.0; 95% CI: 1.3-12.2; p = .02), and less frequent window of exposure to nevirapine (NVP) (aOR: 0.1; 95% CI: 0.02-0.6; p = .01). For the full study sample, there was a strong positive association between duration of exposure to NVP and lumbar spine Z-score (p = .004). HIV-positive patients exposed to long-term cART have a high incidence of low BMD. Tenofovir disoproxil fumarate and ritonavir-boosted protease inhibitors did not seem to be associated with increased risk of low BMD, whereas NVP exposure appeared to have an independent positive association.
Collapse
Affiliation(s)
- Camille Couffignal
- Infection, Antimicrobials, Modeling, Evolution (IAME) UMR 1137, INSERM and Université of Paris, Paris, France
| | - Sami Kolta
- Department of Rheumatology, University Hospital Cochin, Assistance Publique–Hôpitaux de Paris, INSERM UMR-1153, Paris, France
| | - Martin Flamant
- Department of Physiology, University Hospital Bichat, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Charles Cazanave
- Infectious Diseases Department, University Hospital Bordeaux, Bordeaux, France
| | - Jean-Philippe Haymann
- Department of Physiology, University Hospital Tenon, and INSERM UMR_S1155, Paris, France
| | - France Mentré
- Infection, Antimicrobials, Modeling, Evolution (IAME) UMR 1137, INSERM and Université of Paris, Paris, France
| | - Xavier Duval
- Infection, Antimicrobials, Modeling, Evolution (IAME) UMR 1137, INSERM and Université of Paris, Paris, and INSERM CIC1425, Paris, France
| | - Catherine Leport
- Unité COREB (Coordination du Risque Epidémique et Biologique), Assistance Publique–Hôpitaux de Paris, Paris, France
| | - François Raffi
- Infectious Diseases Department, University Hospital Hotel-Dieu, and INSERM CIC 1413, University of Nantes, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Bekker LG, Tatoud R, Dabis F, Feinberg M, Kaleebu P, Marovich M, Ndung'u T, Russell N, Johnson J, Luba M, Fauci AS, Morris L, Pantaleo G, Buchbinder S, Gray G, Vekemans J, Kim JH, Levy Y, Corey L, Shattock R, Makanga M, Williamson C, Dieffenbach C, Goodenow MM, Shao Y, Staprans S, Warren M, Johnston MI. The complex challenges of HIV vaccine development require renewed and expanded global commitment. Lancet 2020; 395:384-388. [PMID: 31806257 DOI: 10.1016/s0140-6736(19)32682-0] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 10/12/2019] [Accepted: 10/29/2019] [Indexed: 02/07/2023]
Affiliation(s)
- Linda-Gail Bekker
- The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
| | | | - Francois Dabis
- France Recherche Nord and Sud Sida-HIV Hépatites, Paris, France
| | - Mark Feinberg
- International AIDS Vaccine Initiative, New York, NY, USA
| | - Pontiano Kaleebu
- Medical Research Council/Uganda Virus Research Institute and The London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda
| | - Mary Marovich
- National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Thumbi Ndung'u
- Africa Health Research Institute, HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa
| | - Nina Russell
- Bill & Melinda Gates Foundation, Seattle, WA, USA
| | | | - Maureen Luba
- AIDS Vaccine Advocacy Coalition, New York, NY, USA
| | - Anthony S Fauci
- National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Lynn Morris
- National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; Center for the AIDS Program of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa; Medical Research Council Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Giuseppe Pantaleo
- Service of Immunology and Allergy and Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Susan Buchbinder
- Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA
| | - Glenda Gray
- South African Medical Research Council, Cape Town, South Africa
| | | | - Jerome H Kim
- International Vaccine Institute, Seoul, South Korea
| | - Yves Levy
- Vaccine Research Institute, Creteil, France; INSERM U955, University Paris-Est Créteil, Créteil, France
| | - Lawrence Corey
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Robin Shattock
- Department of Medicine, Imperial College London, London, UK
| | - Michael Makanga
- European and Developing Countries Clinical Trials Partnership, The Hague, Netherlands
| | - Carolyn Williamson
- Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Carl Dieffenbach
- National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Maureen M Goodenow
- The Office of AIDS Research, National Institutes of Health, Bethesda, MD, USA
| | - Yiming Shao
- State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China
| | | | | | | |
Collapse
|
27
|
Ellouze M, Vigouroux L, Tcherakian C, Woerther PL, Guguin A, Robert O, Surenaud M, Tran T, Calmette J, Barbin T, Perlemuter G, Cassard AM, Launay P, Maxime V, Annane D, Levy Y, Godot V. Overexpression of GILZ in macrophages limits systemic inflammation while increasing bacterial clearance in sepsis in mice. Eur J Immunol 2020; 50:589-602. [PMID: 31840802 DOI: 10.1002/eji.201948278] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Revised: 11/06/2019] [Accepted: 12/12/2019] [Indexed: 12/17/2022]
Abstract
Studies support the beneficial effects of glucocorticoids (GCs) during septic shock, steering research toward the potential role of GC-induced proteins in controlling excessive inflammatory responses. GILZ is a glucocorticoid-induced protein involved in the anti-inflammatory effects of GCs. We investigated whether the overexpression of GILZ specifically limited to monocytes and macrophages (M/M) alone could control inflammation, thus improving the outcome of septic shock in animal models. We also monitored the expression of GILZ in M/M from septic mice and septic-shock patients. M/M from patients and septic mice displayed significantly lower expression of GILZ than those isolated from controls. Furthermore, transgenic mice (Tg-mice) experiencing sepsis, with increased expression of GILZ restricted to M/M, showed lower frequencies of inflammatory monocytes than their littermates and lower plasma levels of inflammatory cytokines. Tg-mice also had lower blood bacterial counts. We further established that the upregulation of GILZ in M/M enhanced their phagocytic capacity in in vivo assays. The increase of GILZ in M/M was also sufficient to improve the survival rates of septic mice. These results provide evidence for a central role of both GILZ and M/M in the pathophysiology of septic shock and a possible clue for the modulation of inflammation in this disease.
Collapse
Affiliation(s)
- Mehdi Ellouze
- Faculty of Medicine, Univ. Paris Est Créteil, Créteil, France.,Vaccine Research Institute-VRI, Créteil, France.,INSERM U955-Team 16, Créteil, France
| | - Lola Vigouroux
- Faculty of Medicine, Univ. Paris Est Créteil, Créteil, France.,Vaccine Research Institute-VRI, Créteil, France.,INSERM U955-Team 16, Créteil, France
| | | | - Paul-Louis Woerther
- Department of Microbiology and Infection Control, Henri-Mondor Hospital, APHP, Créteil, France.,EA 7380 Dynamyc, EnvA, UPEC, Paris-Est University, Créteil, France
| | | | - Olivier Robert
- Faculty of Medicine, Univ. Paris-Sud, France.,INSERM U996, Clamart, France
| | - Mathieu Surenaud
- Faculty of Medicine, Univ. Paris Est Créteil, Créteil, France.,Vaccine Research Institute-VRI, Créteil, France.,INSERM U955-Team 16, Créteil, France
| | - Thi Tran
- Faculty of Medicine, Univ. Paris-Sud, France.,INSERM U996, Clamart, France
| | - Joseph Calmette
- Faculty of Medicine, Univ. Paris-Sud, France.,INSERM U996, Clamart, France
| | - Thomas Barbin
- Faculty of Medicine, Univ. Paris Est Créteil, Créteil, France.,Vaccine Research Institute-VRI, Créteil, France.,INSERM U955-Team 16, Créteil, France
| | - Gabriel Perlemuter
- Faculty of Medicine, Univ. Paris-Sud, Le Kremlin Bicêtre, France.,INSERM U996, Clamart, France.,Service de Gastro-Entérologie, AP-HP, Clamart, France
| | - Anne-Marie Cassard
- Faculty of Medicine, Univ. Paris-Sud, France.,INSERM U996, Clamart, France
| | - Pierre Launay
- Univ. Paris Diderot, Sorbonne Paris Cité, Paris, France.,Laboratoire d'Excellence INFLAMEX, INSERM U1149, Paris, France
| | - Virginie Maxime
- Hôpital Raymond-Poincaré (AP-HP), INSERM U1173, Univ. Versailles SQY, Garches, France
| | - Djillali Annane
- Hôpital Raymond-Poincaré (AP-HP), INSERM U1173, Univ. Versailles SQY, Garches, France
| | - Yves Levy
- Faculty of Medicine, Univ. Paris Est Créteil, Créteil, France.,Vaccine Research Institute-VRI, Créteil, France.,INSERM U955-Team 16, Créteil, France
| | - Véronique Godot
- Faculty of Medicine, Univ. Paris Est Créteil, Créteil, France.,Vaccine Research Institute-VRI, Créteil, France.,INSERM U955-Team 16, Créteil, France
| |
Collapse
|
28
|
Perdiguero B, Gómez CE, García-Arriaza J, Sánchez-Corzo C, Sorzano CÓS, Wilmschen S, von Laer D, Asbach B, Schmalzl C, Peterhoff D, Ding S, Wagner R, Kimpel J, Levy Y, Pantaleo G, Esteban M. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses. Front Immunol 2019; 10:2941. [PMID: 31921191 PMCID: PMC6930178 DOI: 10.3389/fimmu.2019.02941] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Accepted: 11/29/2019] [Indexed: 01/03/2023] Open
Abstract
The generation of a vaccine against HIV-1 able to induce durable protective immunity continues a major challenge. The modest efficacy (31.2%) of the phase III RV144 clinical trial provided the first demonstration that a prophylactic HIV/AIDS vaccine is achievable but emphasized the need for further refinements of vaccine candidates, formulations, and immunization regimens. Here, we analyzed in mice the immunogenicity profile elicited by different homologous and heterologous prime/boost combinations using the modified rhabdovirus VSV-GP combined with DNA or poxviral NYVAC vectors, all expressing trimeric membrane-bound Env (gp145) of HIV-1 96ZM651 clade C, with or without purified gp140 protein component. In cultured cells infected with recombinant VSV-GP or NYVAC viruses, gp145 epitopes at the plasma membrane were recognized by human HIV-1 broadly neutralizing antibodies (bNAbs). In immunized mice, the heterologous combination of VSV-GP and NYVAC recombinant vectors improved the induction of HIV-1 Env-specific humoral and cellular immune responses compared to homologous prime/boost protocols. Specifically, the combination of VSV-GP in the prime and NYVAC in the boost induced higher HIV-1 Env-specific T cell (CD4/CD8 T cells and T follicular helper -Tfh- cells) immune responses compared to the use of DNA or NYVAC vectors in the prime and VSV-GP in the boost. Such enhanced T cell responses correlated with an enhancement of the Env-specific germinal center (GC) B cell population and with a heavily biased Env-specific response toward the Th1-associated IgG2a and IgG3 subclasses, while the other groups showed a Th2-associated IgG1 bias. In summary, our T and B cell population data demonstrated that VSV-GP-based vectors could be taken into consideration as an optimized immunogenic HIV-1 vaccine candidate component against HIV-1 when used for priming in heterologous combinations with the poxvirus vector NYVAC as a boost.
Collapse
Affiliation(s)
- Beatriz Perdiguero
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Carmen Elena Gómez
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Juan García-Arriaza
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Cristina Sánchez-Corzo
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Carlos Óscar S Sorzano
- Biocomputing Unit and Computational Genomics, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| | - Sarah Wilmschen
- Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
| | - Dorothee von Laer
- Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
| | - Benedikt Asbach
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
| | - Christina Schmalzl
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
| | - David Peterhoff
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany
| | - Song Ding
- EuroVacc Foundation, Amsterdam, Netherlands
| | - Ralf Wagner
- Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.,Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany
| | - Janine Kimpel
- Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria
| | - Yves Levy
- Vaccine Research Institute, Créteil, France.,INSERM U955, Paris Est Créteil University, Créteil, France.,AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses, Créteil, France
| | - Giuseppe Pantaleo
- Division of Immunology and Allergy, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
| | - Mariano Esteban
- Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain
| |
Collapse
|
29
|
Orvain C, Lin YL, Jean-Louis F, Hocini H, Hersant B, Bennasser Y, Ortonne N, Hotz C, Wolkenstein P, Boniotto M, Tisserand P, Lefebvre C, Lelièvre JD, Benkirane M, Pasero P, Levy Y, Hüe S. Un stress réplicatif spontané des cellules souches du follicule pileux serait à l’origine de l’inflammation dans l’hidradénite suppurée. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Bouteau A, Kervevan J, Su Q, Zurawski SM, Contreras V, Dereuddre-Bosquet N, Le Grand R, Zurawski G, Cardinaud S, Levy Y, Igyártó BZ. DC Subsets Regulate Humoral Immune Responses by Supporting the Differentiation of Distinct Tfh Cells. Front Immunol 2019; 10:1134. [PMID: 31191525 PMCID: PMC6545976 DOI: 10.3389/fimmu.2019.01134] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 05/07/2019] [Indexed: 12/19/2022] Open
Abstract
To determine the contribution of skin DC subsets in the regulation of humoral immunity, we used a well-characterized antigen targeting system to limit antigen availability and presentation to certain skin-derived DC subsets. Here we show that delivery of foreign antigen to steady state Langerhans cells (LCs) and cDC1s through the same receptor (Langerin) led to, respectively, robust vs. minimal-to-null humoral immune response. LCs, unlike cDC1s, supported the formation of germinal center T follicular helper cells (GC-Tfh) antigen dose-dependently and then, likely licensed by these T cells, some of the LCs migrated to the B cell area to initiate B cell responses. Furthermore, we found that the cDC1s, probably through their superior T cell activation capacity, prevented the LCs from inducing GC-Tfh cells and humoral immune responses. We further show that targeted delivery of cytokines to DCs can be used to modulate DC-induced humoral immune responses, which has important therapeutic potential. Finally, we show that human LCs, unlike monocyte-derived DCs, can support GC Tfh generation in an in vitro autologous system; and in agreement with mouse data, we provide evidence in NHP studies that targeting LCs without adjuvants is an effective way to induce antibody responses, but does not trigger CD8+ T cell responses. Our findings suggest that the major limitations of some relatively ineffective vaccines currently in use or in development might be that (1) they are not formulated to specifically target a certain subset of DCs and/or (2) the antigen dose is not tailored to maximize the intrinsic/pre-programmed capabilities of the specific DC subset. This new and substantial departure from the status quo is expected to overcome problems that have hindered our ability to generate effective vaccines against some key pathogens.
Collapse
Affiliation(s)
- Aurélie Bouteau
- Baylor Scott & White Research Institute, Baylor Institute for Immunology Research, Dallas, TX, United States.,Institute of Biomedical Studies, Baylor University, Waco, TX, United States
| | - Jérôme Kervevan
- Vaccine Research Institute, Créteil, France.,INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France.,Faculté de Médecine, Université Paris-Est Créteil, Créteil, France
| | - Qingtai Su
- Baylor Scott & White Research Institute, Baylor Institute for Immunology Research, Dallas, TX, United States
| | - Sandra M Zurawski
- Baylor Scott & White Research Institute, Baylor Institute for Immunology Research, Dallas, TX, United States.,Vaccine Research Institute, Créteil, France
| | - Vanessa Contreras
- Vaccine Research Institute, Créteil, France.,CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France
| | - Nathalie Dereuddre-Bosquet
- Vaccine Research Institute, Créteil, France.,CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France
| | - Roger Le Grand
- Vaccine Research Institute, Créteil, France.,CEA-Université Paris Sud 11-INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France
| | - Gerard Zurawski
- Baylor Scott & White Research Institute, Baylor Institute for Immunology Research, Dallas, TX, United States.,Vaccine Research Institute, Créteil, France
| | - Sylvain Cardinaud
- Vaccine Research Institute, Créteil, France.,INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France.,Faculté de Médecine, Université Paris-Est Créteil, Créteil, France
| | - Yves Levy
- Vaccine Research Institute, Créteil, France.,INSERM, Unité U955, Institut Mondor de Recherche Biomédicale, Créteil, France.,Faculté de Médecine, Université Paris-Est Créteil, Créteil, France
| | - Botond Z Igyártó
- Baylor Scott & White Research Institute, Baylor Institute for Immunology Research, Dallas, TX, United States
| |
Collapse
|
31
|
Lhomme E, Hejblum B, Lacabaratz C, Wiedemann A, Lelièvre J, Levy Y, Thiebaut R, Richert L. Évaluation de l’immunogénicité cellulaire dans les essais cliniques vaccinaux : un modèle bivarié pour mieux prendre en compte la réponse non spécifique. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
32
|
Paillaud E, Bastuji-Garin S, Plonquet A, Foucat E, Fournier B, Boutin E, Le Thuaut A, Levy Y, Hue S. Combined Plasma Elevation of CRP, Intestinal-Type Fatty Acid-Binding Protein (I-FABP), and sCD14 Identify Older Patients at High Risk for Health Care-Associated Infections. J Gerontol A Biol Sci Med Sci 2019; 73:211-217. [PMID: 28582475 DOI: 10.1093/gerona/glx106] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 05/31/2017] [Indexed: 02/04/2023] Open
Abstract
Background We hypothesized that low-grade inflammation was driven by microbial translocation and associated with an increased risk of health care-associated infections (HAIs). Methods We included 121 patients aged 75 years or over in this prospective cohort study. High-sensitivity C-reactive protein (hs-CRP), I-FABP, and sCD14-as markers for low-grade inflammation, intestinal epithelial barrier integrity, and monocyte activation, respectively-were measured at admission. Results HAIs occurred during hospitalization in 62 (51%) patients. Elevated hs-CRP (≥6.02 mg/L, ie, the median) was associated with a significantly higher HAI risk when I-FABP was in the highest quartile (odds ratio [OR], 4; 95% confidence interval [95% CI], 1.39-11.49; p = .010). In patients with hs-CRP elevation and highest-quartile I-FABP, sCD14 elevation (≥0.65 µg/mL, ie, the median) was associated with an 11-fold higher HAI risk (OR, 10.8; 95% CI, 2.28-51.1; p = .003). Multivariate analyses adjusted for invasive procedures and comorbidities did not change the associations linking the three markers to the HAI risk. Conclusion Increased levels of hs-CRP, I-FABP, and sCD14 may reflect loss of intestinal epithelial barrier integrity with microbial translocation leading to monocyte activation and low-grade inflammation. In our cohort, these markers identified patients at high risk for HAIs.
Collapse
Affiliation(s)
- Elena Paillaud
- Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Henri-Mondor, Département de médecine interne et gériatrie, Creteil, France.,Université Paris Est (UPEC), DHU A-TVB, IMRB, CEpiA (Clinical Epidemiology and Ageing) Unit EA, Creteil, France
| | - Sylvie Bastuji-Garin
- Université Paris Est (UPEC), DHU A-TVB, IMRB, CEpiA (Clinical Epidemiology and Ageing) Unit EA, Creteil, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Service de Santé Publique, Creteil, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Unité de Recherche Clinique (URC Mondor), Creteil, France
| | - Anne Plonquet
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Service d'immunologie biologique, Creteil, France
| | - Emile Foucat
- INSERM U955, team 16, IMRB Créteil, France.,Vaccine Research Institute (VRI), Université Paris Est Créteil, Faculté de Médecine, France
| | - Bénédicte Fournier
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Service de biochimie, Creteil, France
| | - Emmanuelle Boutin
- Université Paris Est (UPEC), DHU A-TVB, IMRB, CEpiA (Clinical Epidemiology and Ageing) Unit EA, Creteil, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Unité de Recherche Clinique (URC Mondor), Creteil, France
| | - Aurélie Le Thuaut
- Université Paris Est (UPEC), DHU A-TVB, IMRB, CEpiA (Clinical Epidemiology and Ageing) Unit EA, Creteil, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Unité de Recherche Clinique (URC Mondor), Creteil, France
| | - Yves Levy
- INSERM U955, team 16, IMRB Créteil, France.,Vaccine Research Institute (VRI), Université Paris Est Créteil, Faculté de Médecine, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Service d'immunologie clinique, Creteil, France
| | - Sophie Hue
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Henri-Mondor, Service d'immunologie biologique, Creteil, France.,INSERM U955, team 16, IMRB Créteil, France.,Vaccine Research Institute (VRI), Université Paris Est Créteil, Faculté de Médecine, France
| |
Collapse
|
33
|
Tissier R, Hocini H, Tchitchek N, Deye N, Legriel S, Pichon N, Daubin C, Hermine O, Carli P, Vivien B, Tréluyer JM, Lefebvre C, Tisserand P, Dubois-Randé JL, Berdeaux A, Ghaleh B, Lelièvre JD, Levy Y, Cariou A. Early blood transcriptomic signature predicts patients' outcome after out-of-hospital cardiac arrest. Resuscitation 2019; 138:222-232. [PMID: 30885824 DOI: 10.1016/j.resuscitation.2019.03.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 02/27/2019] [Accepted: 03/10/2019] [Indexed: 12/24/2022]
Abstract
BACKGROUND Early prognostication is a major challenge after out-of-hospital cardiac arrest (OHCA). AIMS We hypothesized that a genome-wide analysis of blood gene expression could offer new prognostic tools and lines of research. METHODS Sixty-nine patients were enrolled from an ancillary study of the clinical trial NCT00999583 that tested the effect of erythropoietin (EPO) after OHCA. Blood samples were collected in comatose survivors of OHCA at hospital admission and 1 and 3 days after resuscitation. Gene expression profiles were analyzed (Illumina HumanHT-12 V4 BeadChip; >34,000 genes). Patients were classified into two categories representing neurological favorable outcome (cerebral performance category [CPC] = 1-2) vs unfavorable outcome (CPC > 2) at Day 60 after OHCA. Differential and functional enrichment analyses were performed to compare transcriptomic profiles between these two categories. RESULTS Among the 69 enrolled patients, 33 and 36 patients were treated or not by EPO, respectively. Among them, 42% had a favorable neurological outcome in both groups. EPO did not affect the transcriptomic response at Day-0 and 1 after OHCA. In contrast, 76 transcripts differed at Day-0 between patients with unfavorable vs favorable neurological outcome. This signature persisted at Day-1 after OHCA. Functional enrichment analysis revealed a down-regulation of adaptive immunity with concomitant up-regulation of innate immunity and inflammation in patients with unfavorable vs favorable neurological outcome. The transcription of many genes of the HLA family was decreased in patients with unfavorable vs favorable neurological outcome. Concomitantly, neutrophil activation and inflammation were observed. Up-stream regulators analysis showed the implication of numerous factors involved in cell cycle and damages. A logistic regression including a set of genes allowed a reliable prediction of the clinical outcomes (specificity = 88%; Hit Rate = 83%). CONCLUSIONS A transcriptomic signature involving a counterbalance between adaptive and innate immune responses is able to predict neurological outcome very early after hospital admission after OHCA. This deserves confirmation in a larger population.
Collapse
Affiliation(s)
- Renaud Tissier
- Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France.
| | - Hakim Hocini
- Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France
| | - Nicolas Tchitchek
- Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France; CEA - Université Paris Sud 11 - INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Infrastructure, F-92265 Fontenay-aux-Roses, France
| | - Nicolas Deye
- Medical ICU, Inserm U942, Lariboisiere Hospital, APHP, F-75010, Paris, France
| | - Stéphane Legriel
- Intensive Care Unit, Versailles Hospital, Le Chesnay, F-78150, France
| | - Nicolas Pichon
- Intensive Care Unit, University Hospital Dupuytren, Limoges, F-87042, France
| | - Cédric Daubin
- CHU de Caen, Department of Medical Intensive Care, Caen, F-14000, France
| | - Olivier Hermine
- Department of Hematology and INSERM U1163 CNRS ERL 8654, Imagine Institute and Necker Hospital, Paris, F-75015, France
| | - Pierre Carli
- SAMU de Paris, Service d'Anesthésie-Réanimation, Hôpital Universitaire Necker- Enfants Malades, Université Paris Descartes, F-75015, Paris, France
| | - Benoît Vivien
- SAMU de Paris, Service d'Anesthésie-Réanimation, Hôpital Universitaire Necker- Enfants Malades, Université Paris Descartes, F-75015, Paris, France
| | - Jean-Marc Tréluyer
- Clinical Research Unit, Paris Centre and Paris Descartes University, Paris, France
| | - Cécile Lefebvre
- Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France
| | - Pascaline Tisserand
- Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France
| | - Jean-Luc Dubois-Randé
- Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France
| | - Alain Berdeaux
- Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France
| | - Bijan Ghaleh
- Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France; APHP, Hôpitaux Universitaires Henri Mondor, Plateforme de Ressources Biologiques, F-94000, Créteil, France
| | - Jean-Daniel Lelièvre
- Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France
| | - Yves Levy
- Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France.
| | - Alain Cariou
- Service de Réanimation Médicale, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Paris, France
| |
Collapse
|
34
|
Marlin R, Nugeyre MT, Tchitchek N, Parenti M, Lefebvre C, Hocini H, Benjelloun F, Cannou C, Nozza S, Dereuddre-Bosquet N, Levy Y, Barré-Sinoussi F, Scarlatti G, Le Grand R, Menu E. Seminal Plasma Exposures Strengthen Vaccine Responses in the Female Reproductive Tract Mucosae. Front Immunol 2019; 10:430. [PMID: 30915079 PMCID: PMC6423065 DOI: 10.3389/fimmu.2019.00430] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Accepted: 02/18/2019] [Indexed: 01/01/2023] Open
Abstract
HIV-1 sexual transmission occurs mainly via mucosal semen exposures. In the female reproductive tract (FRT), seminal plasma (SP) induces physiological modifications, including inflammation. An effective HIV-1 vaccine should elicit mucosal immunity, however, modifications of vaccine responses by the local environment remain to be characterized. Using a modified vaccinia virus Ankara (MVA) as a vaccine model, we characterized the impact of HIV-1+ SP intravaginal exposure on the local immune responses of non-human primates. Multiple HIV-1+ SP exposures did not impact the anti-MVA antibody responses. However, SP exposures revealed an anti-MVA responses mediated by CD4+ T cells, which was not observed in the control group. Furthermore, the frequency and the quality of specific anti-MVA CD8+ T cell responses increased in the FRT exposed to SP. Multi-parameter approaches clearly identified the cervix as the most impacted compartment in the FRT. SP exposures induced a local cell recruitment of antigen presenting cells, especially CD11c+ cells, and CD8+ T cell recruitment in the FRT draining lymph nodes. CD11c+ cell recruitment was associated with upregulation of inflammation-related gene expression after SP exposures in the cervix. We thus highlight the fact that physiological conditions, such as SP exposures, should be taken into consideration to test and to improve vaccine efficacy against HIV-1 and other sexually transmitted infections.
Collapse
Affiliation(s)
- Romain Marlin
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France.,MISTIC Group, Department of Virology, Institut Pasteur, Paris, France.,Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
| | - Marie-Thérèse Nugeyre
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France.,MISTIC Group, Department of Virology, Institut Pasteur, Paris, France.,Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
| | - Nicolas Tchitchek
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
| | - Matteo Parenti
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France.,Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
| | - Cécile Lefebvre
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France.,Équipe 16 Physiopathologie et Immunothérapies dans l'Infection VIH, Institut Mondor de Recherche Biomédicale - INSERM U955, Créteil, France
| | - Hakim Hocini
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France.,Équipe 16 Physiopathologie et Immunothérapies dans l'Infection VIH, Institut Mondor de Recherche Biomédicale - INSERM U955, Créteil, France
| | - Fahd Benjelloun
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France.,MISTIC Group, Department of Virology, Institut Pasteur, Paris, France
| | - Claude Cannou
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France.,MISTIC Group, Department of Virology, Institut Pasteur, Paris, France
| | - Silvia Nozza
- Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
| | - Nathalie Dereuddre-Bosquet
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France
| | - Yves Levy
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France.,Équipe 16 Physiopathologie et Immunothérapies dans l'Infection VIH, Institut Mondor de Recherche Biomédicale - INSERM U955, Créteil, France.,Groupe Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France
| | - Françoise Barré-Sinoussi
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France.,International Division, Institut Pasteur, Paris, France
| | - Gabriella Scarlatti
- Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France.,Viral Evolution and Transmission Unit, San Raffaele Scientific Institute, Milan, Italy
| | - Roger Le Grand
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France.,Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
| | - Elisabeth Menu
- IDMIT Department, U1184 ≪ Immunology of Viral Infections and Autoimmune Diseases ≫ (IMVA), CEA, IBFJ, Université Paris-Sud, Inserm, Fontenay-Aux-Roses, France.,MISTIC Group, Department of Virology, Institut Pasteur, Paris, France.,Vaccine Research Institute - VRI, Hôpital Henri Mondor, Créteil, France
| |
Collapse
|
35
|
Stark Z, Dolman L, Manolio TA, Ozenberger B, Hill SL, Caulfied MJ, Levy Y, Glazer D, Wilson J, Lawler M, Boughtwood T, Braithwaite J, Goodhand P, Birney E, North KN. Integrating Genomics into Healthcare: A Global Responsibility. Am J Hum Genet 2019; 104:13-20. [PMID: 30609404 DOI: 10.1016/j.ajhg.2018.11.014] [Citation(s) in RCA: 208] [Impact Index Per Article: 41.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 11/20/2018] [Indexed: 01/09/2023] Open
Abstract
Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, totaling over US$4 billion, in at least 14 countries. These national genomic-medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implementation and gathering evidence for wider adoption. We review the diversity of approaches and current progress made by national genomic-medicine initiatives in the UK, France, Australia, and US and provide a roadmap for sharing strategies, standards, and data internationally to accelerate implementation.
Collapse
Affiliation(s)
- Zornitza Stark
- Australian Genomics Health Alliance, Melbourne VIC 3052, Australia; Murdoch Children's Research Institute, Melbourne VIC 3052, Australia; Department of Paediatrics, University of Melbourne, Melbourne VIC 3052, Australia
| | - Lena Dolman
- Global Alliance for Genomics and Health, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada; Ontario Institute for Cancer Research, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada
| | - Teri A Manolio
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-2152, USA
| | - Brad Ozenberger
- All of Us Research Program, National Institutes of Health, Bethesda, MD 20892-2152, USA
| | - Sue L Hill
- National Health Service England, Skipton House, 80 London Road, London SE1 6LH, UK
| | - Mark J Caulfied
- Genomics England, Queen Mary University of London, Dawson Hall, London EC1M 6BQ, UK
| | - Yves Levy
- INSERM (French National Institute for Health and Medical Research), 75654 Paris Cedex 13, France
| | - David Glazer
- Verily Life Sciences, 269 East Grand Avenue, South San Francisco, CA 94080, USA
| | - Julia Wilson
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK
| | - Mark Lawler
- Centre for Cancer Research and Cell Biology, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK
| | - Tiffany Boughtwood
- Australian Genomics Health Alliance, Melbourne VIC 3052, Australia; Murdoch Children's Research Institute, Melbourne VIC 3052, Australia
| | - Jeffrey Braithwaite
- Australian Genomics Health Alliance, Melbourne VIC 3052, Australia; Australian Institute of Health Innovation, Macquarie University, 75 Talavera Road, Sydney, NSW 2113, Australia
| | - Peter Goodhand
- Global Alliance for Genomics and Health, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada; Ontario Institute for Cancer Research, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada
| | - Ewan Birney
- Global Alliance for Genomics and Health, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada; European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton, Cambridge CB10 1SD, UK
| | - Kathryn N North
- Australian Genomics Health Alliance, Melbourne VIC 3052, Australia; Murdoch Children's Research Institute, Melbourne VIC 3052, Australia; Department of Paediatrics, University of Melbourne, Melbourne VIC 3052, Australia; Global Alliance for Genomics and Health, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada.
| |
Collapse
|
36
|
Flamar AL, Bonnabau H, Zurawski S, Lacabaratz C, Montes M, Richert L, Wiedemann A, Galmin L, Weiss D, Cristillo A, Hudacik L, Salazar A, Peltekian C, Thiebaut R, Zurawski G, Levy Y. HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates. PLoS One 2018; 13:e0207794. [PMID: 30500852 PMCID: PMC6267996 DOI: 10.1371/journal.pone.0207794] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Accepted: 11/06/2018] [Indexed: 11/18/2022] Open
Abstract
HIV-1 infection can be controlled by anti-retroviral drug therapy, but this is a lifetime treatment and the virus remains latent and rapidly rebounds if therapy is stopped. HIV-1-infected individuals under this drug regimen have increased rates of cancers, cardiovascular diseases, and autoimmunity due to compromised immunity. A therapeutic vaccine boosting cellular immunity against HIV-1 is therefore desirable and, possibly combined with other immune modulating agents, could obviate the need for long-term drug therapies. An approach to elicit strong T cell-based immunity is to direct virus protein antigens specifically to dendritic cells (DCs), which are the key cell type for controlling immune responses. For eliciting therapeutic cellular immunity in HIV-1-infected individuals, we developed vaccines comprised of five T cell epitope-rich regions of HIV-1 Gag, Nef, and Pol (HIV5pep) fused to monoclonal antibodies that bind either, the antigen presenting cell activating receptor CD40, or the endocytic dendritic cell immunoreceptor DCIR. The study aimed to demonstrate vaccine safety, establish efficacy for broad T cell responses in both primed and naïve settings, and identify one candidate vaccine for human therapeutic development. The vaccines were administered to Rhesus macaques by intradermal injection with poly-ICLC adjuvant. The animals were either i) naïve or, ii) previously primed with modified vaccinia Ankara vector (MVA) encoding HIV-1 Gag, Pol, and Nef (MVA GagPolNef). In the MVA-primed groups, both DC-targeting vaccinations boosted HIV5pep-specific blood CD4+ T cells producing multiple cytokines, but did not affect the MVA-elicited CD8+ T cell responses. In the naive groups, both DC-targeting vaccines elicited antigen-specific polyfunctional CD4+ and CD8+ T cell responses to multiple epitopes and these responses were unchanged by a subsequent MVA GagPolNef boost. In both settings, the T cell responses elicited via the CD40-targeting vaccine were more robust and were detectable in all the animals, favoring further development of the CD40-targeting vaccine for therapeutic vaccination of HIV-1-infected individuals.
Collapse
Affiliation(s)
- Anne-Laure Flamar
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, United States of America
| | - Henri Bonnabau
- Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, United States of America
- Inserm, Bordeaux Population Health Research Center, UMR 1219, Inria SISTM, Université Bordeaux, ISPED, Bordeaux, France
| | - Sandra Zurawski
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, United States of America
| | - Christine Lacabaratz
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service D’immunologie Clinique, Créteil, France
| | - Monica Montes
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, United States of America
| | - Laura Richert
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Inserm, Bordeaux Population Health Research Center, UMR 1219, Inria SISTM, Université Bordeaux, ISPED, Bordeaux, France
| | - Aurelie Wiedemann
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service D’immunologie Clinique, Créteil, France
| | - Lindsey Galmin
- Advanced BioScience Laboratories, Inc., Rockville, MD, United States of America
| | - Deborah Weiss
- Advanced BioScience Laboratories, Inc., Rockville, MD, United States of America
| | - Anthony Cristillo
- Advanced BioScience Laboratories, Inc., Rockville, MD, United States of America
| | - Lauren Hudacik
- Advanced BioScience Laboratories, Inc., Rockville, MD, United States of America
| | | | - Cécile Peltekian
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, United States of America
| | - Rodolphe Thiebaut
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Inserm, Bordeaux Population Health Research Center, UMR 1219, Inria SISTM, Université Bordeaux, ISPED, Bordeaux, France
| | - Gerard Zurawski
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, United States of America
- * E-mail:
| | - Yves Levy
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France
- Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service D’immunologie Clinique, Créteil, France
| |
Collapse
|
37
|
Cheng L, Wang Q, Li G, Banga R, Ma J, Yu H, Yasui F, Zhang Z, Pantaleo G, Perreau M, Zurawski S, Zurawski G, Levy Y, Su L. TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. J Clin Invest 2018; 128:4387-4396. [PMID: 30148455 DOI: 10.1172/jci99005] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Accepted: 07/09/2018] [Indexed: 12/20/2022] Open
Abstract
Activation of HIV-1 reservoirs and induction of anti-HIV-1 T cells are critical to control HIV-1 rebound after combined antiretroviral therapy (cART). Here we evaluated in humanized mice (hu-mice) with persistent HIV-1 infection the therapeutic effect of TLR3 agonist and a CD40-targeting HIV-1 vaccine, which consists of a string of 5 highly conserved CD4+ and CD8+ T cell epitope-rich regions of HIV-1 Gag, Nef, and Pol fused to the C-terminus of a recombinant anti-human CD40 antibody (αCD40.HIV5pep). We show that αCD40.HIV5pep vaccination coadministered with poly(I:C) adjuvant induced HIV-1-specific human CD8+ and CD4+ T cell responses in hu-mice. Interestingly, poly(I:C) treatment also reactivated HIV-1 reservoirs. When administrated in therapeutic settings in HIV-1-infected hu-mice under effective cART, αCD40.HIV5pep with poly(I:C) vaccination induced HIV-1-specific CD8+ T cells and reduced the level of cell-associated HIV-1 DNA (or HIV-1 reservoirs) in lymphoid tissues. Most strikingly, the vaccination significantly delayed HIV-1 rebound after cART cessation. In summary, the αCD40.HIV5pep with poly(I:C) vaccination approach both activates replication of HIV-1 reservoirs and enhances the anti-HIV-1 T cell response, leading to a reduced level of cell-associated HIV-1 DNA or reservoirs. Our proof-of-concept study has significant implication for the development of CD40-targeting HIV-1 vaccine to enhance anti-HIV-1 immunity and reduce HIV-1 reservoirs in patients with suppressive cART.
Collapse
Affiliation(s)
- Liang Cheng
- Lineberger Comprehensive Cancer Center, and.,Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| | - Qi Wang
- Lineberger Comprehensive Cancer Center, and
| | | | - Riddhima Banga
- Service of Immunology and Allergy and.,Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | | | | | | | - Zheng Zhang
- Lineberger Comprehensive Cancer Center, and.,Research Center for Clinical & Translational Medicine, Beijing 302 Hospital, Beijing, China
| | - Giuseppe Pantaleo
- Service of Immunology and Allergy and.,Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Matthieu Perreau
- Service of Immunology and Allergy and.,Swiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland
| | - Sandra Zurawski
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France.,Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, USA
| | - Gerard Zurawski
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France.,Baylor Institute for Immunology Research and INSERM U955, Dallas, Texas, USA
| | - Yves Levy
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France.,Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique, Créteil, France
| | - Lishan Su
- Lineberger Comprehensive Cancer Center, and.,Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
| |
Collapse
|
38
|
Rosenbaum P, Tchitchek N, Joly C, Stimmer L, Hocini H, Dereuddre-Bosquet N, Beignon AS, Chapon C, Levy Y, Le Grand R, Martinon F. Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine. Front Immunol 2018; 9:870. [PMID: 29922280 PMCID: PMC5996922 DOI: 10.3389/fimmu.2018.00870] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Accepted: 04/09/2018] [Indexed: 01/05/2023] Open
Abstract
New vaccine design approaches would be greatly facilitated by a better understanding of the early systemic changes, and those that occur at the site of injection, responsible for the installation of a durable and oriented protective response. We performed a detailed characterization of very early infection and host response events following the intradermal administration of the modified vaccinia virus Ankara as a live attenuated vaccine model in non-human primates. Integrated analysis of the data obtained from in vivo imaging, histology, flow cytometry, multiplex cytokine, and transcriptomic analysis using tools derived from systems biology, such as co-expression networks, showed a strong early local and systemic inflammatory response that peaked at 24 h, which was then progressively replaced by an adaptive response during the installation of the host response to the vaccine. Granulocytes, macrophages, and monocytoid cells were massively recruited during the local innate response in association with local productions of GM-CSF, IL-1β, MIP1α, MIP1β, and TNFα. We also observed a rapid and transient granulocyte recruitment and the release of IL-6 and IL-1RA, followed by a persistent phase involving inflammatory monocytes. This systemic inflammation was confirmed by molecular signatures, such as upregulations of IL-6 and TNF pathways and acute phase response signaling. Such comprehensive approaches improve our understanding of the spatiotemporal orchestration of vaccine-elicited immune response, in a live-attenuated vaccine model, and thus contribute to rational vaccine development.
Collapse
Affiliation(s)
- Pierre Rosenbaum
- Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, CEA - Université Paris Sud 11 - INSERM U1184, Fontenay-aux-Roses, France.,Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Nicolas Tchitchek
- Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, CEA - Université Paris Sud 11 - INSERM U1184, Fontenay-aux-Roses, France
| | - Candie Joly
- Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, CEA - Université Paris Sud 11 - INSERM U1184, Fontenay-aux-Roses, France
| | - Lev Stimmer
- CEA - INSERM, MIRCen, UMS27, Fontenay-aux-Roses, France.,INSERM U1169, Kremlin-Bicêtre, France
| | - Hakim Hocini
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France.,INSERM U955, Henri Mondor Hospital, University of Paris East, Créteil, France
| | - Nathalie Dereuddre-Bosquet
- Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, CEA - Université Paris Sud 11 - INSERM U1184, Fontenay-aux-Roses, France
| | - Anne-Sophie Beignon
- Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, CEA - Université Paris Sud 11 - INSERM U1184, Fontenay-aux-Roses, France.,Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Catherine Chapon
- Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, CEA - Université Paris Sud 11 - INSERM U1184, Fontenay-aux-Roses, France.,Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Yves Levy
- Vaccine Research Institute, Henri Mondor Hospital, Créteil, France.,INSERM U955, Henri Mondor Hospital, University of Paris East, Créteil, France
| | - Roger Le Grand
- Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, CEA - Université Paris Sud 11 - INSERM U1184, Fontenay-aux-Roses, France.,Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| | - Frédéric Martinon
- Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, CEA - Université Paris Sud 11 - INSERM U1184, Fontenay-aux-Roses, France.,Vaccine Research Institute, Henri Mondor Hospital, Créteil, France
| |
Collapse
|
39
|
Curtis-Wetton E, Ross J, Levy Y, Vilchez J, Ochala J. What is wrong with nuclei in Transportin 3 (TPNO3)-related muscular dystrophy? Neuromuscul Disord 2018. [DOI: 10.1016/s0960-8966(18)30315-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
40
|
Altaf S, Sakib S, Levy Y, Sadler M. Abstract No. 681 Predictability of D-dimer levels in detecting pulmonary embolism in the sickle cell population. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.726] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
41
|
|
42
|
Guillevin L, Leon A, Levy Y, Bletry O, Gayraud M, Andreu G, Godeau P. Treatment of Progressive Systemic Sclerosis with Plasma Exchange. Seven Cases. Int J Artif Organs 2018. [DOI: 10.1177/039139888300600608] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Seven patients, 4 women and 3 men afflicted with severe progressive systemic sclerosis (PSS) were treated with Plasma Exchange after failure of different other treatment. All patients presented Raynaud phenomenon and arthritis, 6 patients presented extensive skin lesions, 5 of them digestive manifestations, 3 pulmonary fibrosis. In one case PSS was associated with polymyositis, one patient presented bilateral recurrent cornea ulcerations, (Sjögren Syndrom) and one patient numerous skin ulcerations. In 5 patients adjuvant corticosteroid therapy was given during the course of PE. In 3 patients PE must be stopped after one or two sessions because of insufficient venous access. Among the 4 other patients 8 to 20 PE were performed: the patient with cornea ulcerations became blind during the treatment, skin ulcerations and severe Raynaud phenomenon did not improved in two other patients. Benefit of PE was noted in only one patient with regressive myositis, and improvement of articular and cutaneous symptoms. Therefore, PE are not useful in most patients afflicted with PSS, they are difficult to realize in numerous patients and did not improve clinical symptoms in most cases.
Collapse
Affiliation(s)
- L. Guillevin
- Hôpital Avicenne - Université Paris XIII Bobigny - France
| | - A. Leon
- Hôpital Avicenne - Université Paris XIII Bobigny - France
| | - Y. Levy
- Hôpital Avicenne - Université Paris XIII Bobigny - France
| | - O. Bletry
- Hôpital de la Pitie Salpetriere Paris, France
| | - M. Gayraud
- Hôpital Avicenne - Université Paris XIII Bobigny - France
| | - G. Andreu
- Hôpital Avicenne - Université Paris XIII Bobigny - France
| | - P. Godeau
- Hôpital de la Pitie Salpetriere Paris, France
| |
Collapse
|
43
|
Abstract
Serological tests of 35 patients suffering from inflammatory bowel disease were compared to those of 35 healthy controls. The tests were performed using the indirect immunoperoxidase assay. Ninety-three per cent of 15 patients with Crohn's disease had IgG antibodies against Chlamydia, compared to 26% in the control group. In the 20 patients with ulcerative colitis, 45% had IgG antibodies against Chlamydia, compared to 10% in the control group. High serum titres of IgG antibodies were found in most of the patients with inflammatory bowel disease, mainly with Crohn's disease, while weak reactions appeared in most of the controls in which antibodies were detected. These results suggest a high incidence of Chlamydia infection in the studied patients with inflammatory bowel disease, especially in those with Crohn's disease. The possible association between Chlamydia trachomatis and inflammatory bowel disease is discussed.
Collapse
Affiliation(s)
- R Orda
- Department of Surgery A, Assaf Harofeh Medical Center, Zerifin, Israel
| | | | | | | | | |
Collapse
|
44
|
Jalal Z, Petit J, Gronier C, Godart F, Mauri L, Dauphin C, Hascoet S, Lefort B, Lachaud M, Piot D, Dinet M, Levy Y, Fraisse A, Fraisse A, Ovaert C, Lusson J, Thambo J, Baruteau A. Long-term outcomes after percutaneous closure of isolated secundum atrial septal defect in the young: A nationwide cohort study. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2017.11.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Cheng L, Zhang Z, Li G, Li F, Wang L, Zhang L, Zurawski SM, Zurawski G, Levy Y, Su L. Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system. Vaccine 2017; 35:6143-6153. [PMID: 28958808 PMCID: PMC5641266 DOI: 10.1016/j.vaccine.2017.09.052] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Revised: 08/31/2017] [Accepted: 09/17/2017] [Indexed: 01/04/2023]
Abstract
TLR ligands (TLR-Ls) represent a class of novel vaccine adjuvants. However, their immunologic effects in humans remain poorly defined in vivo. Using a humanized mouse model with a functional human immune system, we investigated how different TLR-Ls stimulated human innate immune response in vivo and their applications as vaccine adjuvants for enhancing human cellular immune response. We found that splenocytes from humanized mice showed identical responses to various TLR-Ls as human PBMCs in vitro. To our surprise, various TLR-Ls stimulated human cytokines and chemokines differently in vivo compared to that in vitro. For example, CpG-A was most efficient to induce IFN-α production in vitro. In contrast, CpG-B, R848 and Poly I:C stimulated much more IFN-α than CpG-A in vivo. Importantly, the human innate immune response to specific TLR-Ls in humanized mice was different from that reported in C57BL/6 mice, but similar to that reported in nonhuman primates. Furthermore, we found that different TLR-Ls distinctively activated and mobilized human plasmacytoid dendritic cells (pDCs), myeloid DCs (mDCs) and monocytes in different organs. Finally, we showed that, as adjuvants, CpG-B, R848 and Poly I:C can all enhance antigen specific CD4+ T cell response, while only R848 and Poly I:C induced CD8+ cytotoxic T cells response to a CD40-targeting HIV vaccine in humanized mice, correlated with their ability to activate human mDCs but not pDCs. We conclude that humanized mice serve as a highly relevant model to evaluate and rank the human immunologic effects of novel adjuvants in vivo prior to testing in humans.
Collapse
Affiliation(s)
- Liang Cheng
- Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - Zheng Zhang
- Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - Guangming Li
- Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - Feng Li
- Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - Li Wang
- Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States
| | - Liguo Zhang
- Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
| | - Sandra M Zurawski
- Baylor Institute for Immunology Research, Dallas, TX 75204, United States; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d'immunologie clinique, 94010 Créteil, France
| | - Gerard Zurawski
- Baylor Institute for Immunology Research, Dallas, TX 75204, United States; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d'immunologie clinique, 94010 Créteil, France
| | - Yves Levy
- Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, Créteil, France; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Service d'immunologie clinique, 94010 Créteil, France
| | - Lishan Su
- Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
| |
Collapse
|
46
|
Abstract
Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed "targeted biological medication" is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease.
Collapse
Affiliation(s)
- R Pikman
- 1 Israel Defense Forces Medical Corps, Ramat Gan, Israel
| | - S Kivity
- 2 Department of Medicine A, Sheba Medical Center, Tel-Hashomer, Israel.,3 The Zabludovicz Center for Autoimmune Diseases.,4 The Dr Pinchas Borenstein Talpiot Medical Leadership Program 2013; and Sheba Medical Center, Tel-Hashomer, Israel.,5 Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel
| | - Y Levy
- 6 Department of Medicine E, Meir Medical Center, Kfar Saba, Israel; affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - M-T Arango
- 3 The Zabludovicz Center for Autoimmune Diseases.,7 Doctoral Program in Biomedical Sciences, Universidad del Rosario, Bogotá-Colombia
| | - J Chapman
- 5 Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.,8 Department of Neurology, Sagol Neuroscience Center, Sheba Medical Center, Tel-Hashomer, Israel
| | - H Yonath
- 2 Department of Medicine A, Sheba Medical Center, Tel-Hashomer, Israel.,5 Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.,9 The Danek Gartner Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer, Israel
| | - Y Shoenfeld
- 3 The Zabludovicz Center for Autoimmune Diseases.,5 Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.,10 Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel Aviv University, Israel
| | - S G Gofrit
- 2 Department of Medicine A, Sheba Medical Center, Tel-Hashomer, Israel
| |
Collapse
|
47
|
Marlin R, Nugeyre MT, Tchitchek N, Parenti M, Hocini H, Benjelloun F, Cannou C, Dereuddre-Bosquet N, Levy Y, Barré-Sinoussi F, Scarlatti G, Le Grand R, Menu E. Modified Vaccinia Virus Ankara Vector Induces Specific Cellular and Humoral Responses in the Female Reproductive Tract, the Main HIV Portal of Entry. J Immunol 2017; 199:1923-1932. [PMID: 28760882 DOI: 10.4049/jimmunol.1700320] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 07/03/2017] [Indexed: 11/19/2022]
Abstract
The female reproductive tract (FRT) is one of the major mucosal invasion sites for HIV-1. This site has been neglected in previous HIV-1 vaccine studies. Immune responses in the FRT after systemic vaccination remain to be characterized. Using a modified vaccinia virus Ankara (MVA) as a vaccine model, we characterized specific immune responses in all compartments of the FRT of nonhuman primates after systemic vaccination. Memory T cells were preferentially found in the lower tract (vagina and cervix), whereas APCs and innate lymphoid cells were mainly located in the upper tract (uterus and fallopian tubes). This compartmentalization of immune cells in the FRT was supported by transcriptomic analyses and a correlation network. Polyfunctional MVA-specific CD8+ T cells were detected in the blood, lymph nodes, vagina, cervix, uterus, and fallopian tubes. Anti-MVA IgG and IgA were detected in cervicovaginal fluid after a second vaccine dose. Thus, systemic vaccination with an MVA vector elicits cellular and Ab responses in the FRT.
Collapse
Affiliation(s)
- Romain Marlin
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France.,Mucosal Innate Immunity and Sexually Transmitted Infections Control Group, Department of Virology, Institut Pasteur, 75015 Paris, France.,Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France
| | - Marie-Thérèse Nugeyre
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France.,Mucosal Innate Immunity and Sexually Transmitted Infections Control Group, Department of Virology, Institut Pasteur, 75015 Paris, France.,Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France
| | - Nicolas Tchitchek
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France
| | - Matteo Parenti
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France
| | - Hakim Hocini
- Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France.,Faculté de Médecine, Université Paris-Est, INSERM U955, 94010 Créteil, France
| | - Fahd Benjelloun
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France.,Mucosal Innate Immunity and Sexually Transmitted Infections Control Group, Department of Virology, Institut Pasteur, 75015 Paris, France
| | - Claude Cannou
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France.,Mucosal Innate Immunity and Sexually Transmitted Infections Control Group, Department of Virology, Institut Pasteur, 75015 Paris, France
| | - Nathalie Dereuddre-Bosquet
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France
| | - Yves Levy
- Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France.,Faculté de Médecine, Université Paris-Est, INSERM U955, 94010 Créteil, France.,Service d'Immunologie Clinique, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique-Hôpitaux de Paris, 94010 Créteil, France
| | - Françoise Barré-Sinoussi
- Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France.,Division Internationale, Institut Pasteur, 75015 Paris, France; and
| | - Gabriella Scarlatti
- Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France.,Viral Evolution and Transmission Unit, San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Roger Le Grand
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France.,Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France
| | - Elisabeth Menu
- Immunologie des Infections Virales et des Maladies Auto-immunes (ImVA)/Infrastructure Nationale pour la Modélisation des Maladies Infectieuses Humaines et les Thérapies Innovantes (IDMIT)/Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)/Direction de la Recherche Fondamentale (DRF)/Institut des Maladies Emergentes et des Traitements Innovants (IMETI), Université Paris-Sud, INSERM U1184, 92265 Fontenay-Aux-Roses, France; .,Mucosal Innate Immunity and Sexually Transmitted Infections Control Group, Department of Virology, Institut Pasteur, 75015 Paris, France.,Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France
| |
Collapse
|
48
|
Brezar V, Hani L, Surenaud M, Hubert A, Lacabaratz C, Lelièvre JD, Levy Y, Seddiki N. Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine. PLoS Pathog 2017; 13:e1006489. [PMID: 28708863 PMCID: PMC5529021 DOI: 10.1371/journal.ppat.1006489] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Revised: 07/26/2017] [Accepted: 06/23/2017] [Indexed: 12/25/2022] Open
Abstract
The potential benefit in using IL-2 in immunotherapy for cancer and autoimmunity has been linked to the modulation of immune responses, which partly relies on a direct effect on Tregs populations. Here, we revisited the role of IL-2 in HIV infection and investigated whether its use as an adjuvant with therapeutic vaccination, impacts on HIV-specific responses. Antiretroviral therapy treated-patients were randomized to receive 4 boosts of vaccination (ALVACHIV/Lipo-6T, weeks 0/4/8/12) followed by 3 cycles of IL-2 (weeks 16/24/32) before treatment interruption (TI) at week40. IL-2 administration increased significantly HIV-specific CD4+CD25+CD134+ T-cell responses, which inversely correlated with viral load after TI (r = -0.7, p <0.007) in the vaccine/IL-2 group. IL-2 increased global CD25+CD127lowFoxP3+Tregs (p <0.05) while it decreased HIV- but not CMV- specific CD39+FoxP3+CD25+CD134+Tregs (p <0.05). HIV-specific Tregs were inversely correlated with IFN-γ producing specific-effectors (p = 0.03) and positively correlated with viral load (r = 0.7, p = 0.01), revealing their undesired presence during chronic infection. Global Tregs, but not HIV-specific Tregs, inversely correlated with a decrease in exhausted PD1+CD95+ T-cells (p = 0.001). Altogether, our results underline the negative impact of HIV-specific Tregs on HIV-specific effectors and reveal the beneficial use of IL-2 as an adjuvant as its administration increases global Tregs that impact on T-cell exhaustion and decreases HIV-specific CD39+Tregs by shifting the balance towards effectors. Interleukin-2 (IL-2) has been used in immunotherapy for cancer and autoimmunity and its beneficial effect has been linked to the modulation of immune responses, which partly relies on a direct effect on Tregs populations. In this study, we assessed the role of IL-2 in HIV infection and investigated whether its use as an adjuvant with therapeutic vaccination, impacts on HIV-specific responses. We show that IL-2 administration increased HIV-specific CD4+CD25+CD134+ T-cell responses which inversely correlated with viral load after treatment interruption in the vaccine/IL-2 group. We also show that IL-2 increased global CD25+CD127lowFoxP3+Tregs while it decreased HIV- but not CMV- specific CD39+FoxP3+CD25+CD134+Tregs. Moreover, we show that HIV-specific Tregs were inversely correlated with IFN-γ-producing specific-effectors and positively correlated with viral load. Moreover, we show that global Tregs, but not HIV-specific Tregs, inversely correlated with a decrease in exhausted PD1+CD95+ T-cells. Altogether, our results underline the negative impact of HIV-specific Tregs on HIV-specific effectors and reveal the beneficial use of IL-2 as an adjuvant as its administration increases global Tregs that impact on T-cell exhaustion and decreases HIV-specific CD39+Tregs by shifting the balance towards effectors.
Collapse
Affiliation(s)
- Vedran Brezar
- Inserm, U955, Equipe 16, Créteil, Paris, France
- Université Paris Est, Faculté de médecine, Créteil, Paris, France
- Vaccine Research Institute (VRI), Créteil, Paris, France
| | - Lylia Hani
- Inserm, U955, Equipe 16, Créteil, Paris, France
- Université Paris Est, Faculté de médecine, Créteil, Paris, France
- Vaccine Research Institute (VRI), Créteil, Paris, France
| | - Mathieu Surenaud
- Inserm, U955, Equipe 16, Créteil, Paris, France
- Université Paris Est, Faculté de médecine, Créteil, Paris, France
- Vaccine Research Institute (VRI), Créteil, Paris, France
| | - Audrey Hubert
- Inserm, U955, Equipe 16, Créteil, Paris, France
- Université Paris Est, Faculté de médecine, Créteil, Paris, France
- Vaccine Research Institute (VRI), Créteil, Paris, France
| | - Christine Lacabaratz
- Inserm, U955, Equipe 16, Créteil, Paris, France
- Université Paris Est, Faculté de médecine, Créteil, Paris, France
- Vaccine Research Institute (VRI), Créteil, Paris, France
| | - Jean-Daniel Lelièvre
- Inserm, U955, Equipe 16, Créteil, Paris, France
- Université Paris Est, Faculté de médecine, Créteil, Paris, France
- Vaccine Research Institute (VRI), Créteil, Paris, France
- AP-HP, Hôpital H. Mondor - A. Chenevier, Service d'immunologie clinique et maladies infectieuses, Créteil, Paris, France
| | - Yves Levy
- Inserm, U955, Equipe 16, Créteil, Paris, France
- Université Paris Est, Faculté de médecine, Créteil, Paris, France
- Vaccine Research Institute (VRI), Créteil, Paris, France
- AP-HP, Hôpital H. Mondor - A. Chenevier, Service d'immunologie clinique et maladies infectieuses, Créteil, Paris, France
- * E-mail: (NS); (YL)
| | - Nabila Seddiki
- Inserm, U955, Equipe 16, Créteil, Paris, France
- Université Paris Est, Faculté de médecine, Créteil, Paris, France
- Vaccine Research Institute (VRI), Créteil, Paris, France
- * E-mail: (NS); (YL)
| |
Collapse
|
49
|
Keita A, Toure A, Sow M, Raoul H, Magassouba N, Delaporte E, Etard JF, Abel L, Ayouba A, Baize S, Bangoura K, Barry A, Barry M, Cissé M, Delaporte E, Delmas C, Desclaux A, Diallo S, Diallo M, Diallo M, Étard JF, Etienne C, Faye O, Fofana I, Granouillac B, Hébert E, Izard S, Kassé D, Keita A, Koivugui L, Kpamou C, Lacarabaratz C, Leroy S, Marchal C, Levy Y, Magassouba N, March L, Msellati P, Niane H, Peeters M, Pers YM, Raoul H, Sacko S, Savané I, Sow M, Taverne B, Touré A, Traoré F. Extraordinary long-term and fluctuating persistence of Ebola virus RNA in semen of survivors in Guinea: implications for public health. Clin Microbiol Infect 2017; 23:412-413. [DOI: 10.1016/j.cmi.2016.11.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2016] [Revised: 09/01/2016] [Accepted: 11/02/2016] [Indexed: 11/16/2022]
|
50
|
Weisz Hubshman M, Basel-Vanagaite L, Krauss A, Konen O, Levy Y, Garty BZ, Smirin-Yosef P, Maya I, Lagovsky I, Taub E, Marom D, Gaash D, Shichrur K, Avigad S, Hayman-Manzur L, Villa A, Sobacchi C, Shohat M, Yaniv I, Stein J. Homozygous deletion of RAG1, RAG2 and 5' region TRAF6 causes severe immune suppression and atypical osteopetrosis. Clin Genet 2017; 91:902-907. [PMID: 27808398 DOI: 10.1111/cge.12916] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 10/24/2016] [Accepted: 10/30/2016] [Indexed: 01/17/2023]
Abstract
Mutations of several genes have been implicated in autosomal recessive osteopetrosis (OP), a disease caused by impaired function and differentiation of osteoclasts. Severe combined immune deficiencies (SCID) can likewise result from different genetic mutations. We report two siblings with SCID and an atypical phenotype of OP. A biallelic microdeletion encompassing the 5' region of TRAF6, RAG1 and RAG2 genes was identified. TRAF6, a tumor necrosis factor receptor-associated family member, plays an important role in T cell signaling and in RANKL-dependent osteoclast differentiation and activation but its role in human OP has not been previously reported. The RAG proteins are essential for recombination of B and T cell receptors, and for the survival and differentiation of these cells. This is the first study to report a homozygous deletion of TRAF6 as a cause of human disease.
Collapse
Affiliation(s)
- M Weisz Hubshman
- Pediatric Genetics Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.,Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - L Basel-Vanagaite
- Pediatric Genetics Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.,Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Felsenstein Medical Research Center, Petach Tikva, Israel
| | - A Krauss
- Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - O Konen
- Radiology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - Y Levy
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Kipper Institute of Immunology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - B Z Garty
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Felsenstein Medical Research Center, Petach Tikva, Israel.,Kipper Institute of Immunology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - P Smirin-Yosef
- Felsenstein Medical Research Center, Petach Tikva, Israel.,Genomic Bioinformatics Laboratory, Department of Molecular Biology, Ariel University, Ariel, Israel
| | - I Maya
- Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva, Israel
| | - I Lagovsky
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - E Taub
- Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva, Israel
| | - D Marom
- Pediatric Genetics Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.,Raphael Recanati Genetic Institute, Rabin Medical Center, Petach Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - D Gaash
- Hemato-Oncology Department, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - K Shichrur
- Hemato-Oncology Department, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - S Avigad
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Felsenstein Medical Research Center, Petach Tikva, Israel.,Hemato-Oncology Department, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - L Hayman-Manzur
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Pathology Department, Rabin Medical Center, Petach Tikva, Israel
| | - A Villa
- CNR/IRGB, UOS Milan Unit, Milan, Italy.,Humanitas Clinical and Research Center, Milan, Italy
| | - C Sobacchi
- CNR/IRGB, UOS Milan Unit, Milan, Italy.,Humanitas Clinical and Research Center, Milan, Italy
| | - M Shohat
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Bioinformatics Unit, Cancer Center, Sheba Medical Center, Tel Aviv, Israel.,Genetic Institute, Maccabi Megalab, Rehovot, Israel
| | - I Yaniv
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - J Stein
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Bone Marrow Transplantation Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| |
Collapse
|